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Chapter 1 
General Introduction,
15
1.1 Left Ventricular Hypertrophy.
1.1.1 Definition.
Left ventricular hypertrophy is an increase in left ventricular mass in response to 
stimuli such as hypertension, exercise and high output cardiac states. As this process 
is an extension of normal growth patterns and initially a protective mechanism an 
arbitrary cut-off is required. This is best defined by the study of a group of normal 
volunteers and using the 95*^  ^centile as the cut-off. Numerous numerical definitions 
exist; the Framingham group studied 846 normal volunteers using echocardiographic 
measurements and found the cut-off to be 131g/m2 in men and 100g/m2 in women. 
(Levy 1987)
1.1.2 Prevalence,
The prevalence of LVH depends on the cohort studied, the method used and the age 
and sex of the cohort. The Framingham study demonstrated a prevalence of 2.1% 
using ECG criteria and 16% using echo criteria in the general population.
Additionally the Framingham group demonstrated a progressive increase in 
prevalence vrith age, which was independent of confounding variables. (Levy 1990) 
Echocardiography identified 7-10 times more cases of increased cardiac mass 
than ECG. (Savage 1979)
1.1.3 Incidence.
The incidence of LVH is higher than the data for prevalence would suggest due to the 
high mortality rate of the condition.
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Using ECG-LVH the Framingham group demonstrated a close relationship 
between systolic BP and development of LVH. 50% of patients with a systolic BP of 
over 1 SOmmHg developed ECG-LVH in the twelve year follow-up of the study. 
(Kannel 1996)
Using Echo determined LVH the same group demonstrated that a 20mmHg 
increase in the systolic blood pressure resulted in a 43% increase in men and a 23% 
increase in women in the development of LVH. Age, myocardial infarction and 
obesity were also important independent predictors. (Levy 1988)
1.1.4 Diagnosis of LVH.
The diagnosis of left ventricular hypertrophy clinically is difficult and inaccurate. 
Therefore from any early stage additional means were employed.
Chest radiography.
Chest x-rays have been used to detect LVH however this an inaccurate means of 
detection that requires left ventricular dilatation to be present. Therefore this 
technique has been largely abandoned.
Electrocardiogram.
It was appreciated soon after the advent of electrocardiography that the presence of 
left ventricular hypertrophy resulted in characteristic ECG changes (Einthoven 1906). 
Specific criteria were first described in the 1940’s by a variety of investigators (Sach 
1950). In 1949 Sokolow and Lyon published their widely cited paper whose findings 
were based on the review of ECGs fi-om hypertensive patients thought to have LVH in 
comparison to normotensive subjects (Sokolow 1949). They reported that the 
characteristic findings were;
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1. A low or biphasic T wave in association with depression of the ST-T segment in 
leads V5 and V6. In later stages this resulted in inversion of the T wave in the 
above leads.
2. An increase in the precordial voltages.
They reported that LVH could be detected by abnormalities in the QRS complex in 
which the R wave in V 5 or V6 exceeded 26mm and/or the sum of the R wave in V5 
and the S wave in VI exceeded 35mm.
Numerous other systems have been described and mostly are a variation on the theme 
of the above system. Most notably by Romhilt-Estes (Romhilt 1968) and the Cornell 
voltage (Casale 1985) criteria.
These methods have subsequently been examined using more accurate techniques of 
assessing the presence of LVH namely echocardiography. This has revealed a high 
specificity (as high as 100% in some studies) however a low sensitivity (as low as 
20%) for almost all ECG criteria.
Echocardiography.
M-mode echocardiography can provide direct measurements of left ventricular 
chamber size and wall thickness. The first methods using M-mode echocardiography 
were validated using quantitative angiography (Troy 1972) or assumed geometric 
models of the left ventricle (Bennet 1975).
Broadly speaking all early echocardiographic techniques were based on the premise 
that the volume of the myocardium was equal to the total volume contained within the 
epicardial borders minus the chamber volume. The muscle volume was then 
converted to mass by multiplying the specific gravity of the cardiac muscle.
These techniques were fiuther advanced by Reichek and Devereux (1977) who 
applied multiple geometric models and demonstrated the accuracy of these techniques
18
by comparison with post-mortem measured left ventricular mass. It should be 
accepted, however, that all these models work best in subjects with normal left 
ventricular geometry.
Following the advent of 2D echocardiography there was further interest in developing 
new geometric models. The most accurate model appeared to be Simpson’s rule 
method. In this method the myocardium represented a series of thick-walled, hollow 
cylinders. The volume of each cylinder is then determined by planimetry of muscle 
area and section height. The myocardial area of each cylinder is determined by direct 
measurement of the interval between multiple short axis cross-sections. This method 
was accurate in vitro but could not be reproduced in vivo (Helak 1981). A simplified 
version of Simpson’s rule was devised which used a single short axis section at 
papillary muscle level for determination of myocardial area and minor cavity area and 
uses apical views for determination of left ventricular epicardial and endocardial 
length. This technique was found to be much more reproducible and Reichek and 
colleagues demonstrated a high correlation between calculated LV mass and actual 
weight at post mortem (r=0.93) (Reichek 1983).
Computerised Tomography and Magnetic resonance Imaging.
MRI is probably the most accurate non-invasive method for the assessment of 
LVH. There are, however, no major studies linking MRI defined left ventricular 
mass with any cardiovascular outcomes. Limited availability remains this 
method’s major limitation
1.1.5 The Importance of LVH.
Sir Thomas Lewis described graphically in his classic monograph the mode of death 
in patients with hypertension (Lewis 1940). It was not, as might have been expected, 
firom myocardial infarction or cerebrovascular accident, but fi*om progressive heart
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failure consequent upon the unrelenting development of LVH with no effective 
method of off-loading the ventricle . It is therefore not surprising, if underemphasised, 
that all major antihypertensive trials have shown a substantial reduction in death from 
hypertensive heart failure. However despite this reduction in hypertensive heart 
failure, LVH still confers an adverse risk for coronary artery disease and sudden 
cardiac death and thus, still constitutes a major cardiovascular risk factor.
Much of the information on LVH as a risk factor comes from the Framingham 
Study, which was set up in the late 1940s to follow up a large cohort of healthy adults 
and to identify factors of risk for subsequent cardiovascular morbidity and mortality 
(Kannel 1970). The authors used the ECG as a means of identifying LVH. In those 
early years this proved to be an effective screening investigation. The study showed 
that the presence of definite LVH (defined as ECG voltage criteria plus ST-T change) 
doubled the risk of cardiovascular disease in comparison to hypertension alone. This 
increased risk could not be explained on the basis of age, sex, level of blood pressure 
or other associated risk factors. The importance of LVH as a risk factor for coronary 
artery disease is even more striking, with a two to three fold increase in the number of 
myocardial infarctions where LVH is present on the ECG. Sudden death is increased 
by a factor of five. LVH is an independent risk factor for sudden cardiac death in men 
independent of the presence of coronary disease, although a less clear relationship 
was seen in women (Kregger 1987).
The Framingham findings were confirmed in a large study from Glasgow, 
which assessed the implications of ECG LVH (Dunn 1990). This study showed an 
increased risk, associated with definite LVH but, in addition, voltage LVH (known in 
the Framingham study as possible LVH) was shown to carry an increased risk, which
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could not be explained on the basis of BP alone. The risk was greater in men at all 
levels of BP, and was considerably magnified by smoking.
1.2 Pathology of Left Ventricular Hypertrophy.
Left ventricular hypertrophy occurs initially as an adaptive process. When the heart is 
exposed to a haemodynamic burden it can compensate by one of three mechanisms.
1. Use the Frank-Starling equation to increase crossbridge formation.
2. Augment muscle mass to cope with the extra load.
3. Recruit neurohormonal mechanisms to increase contractility.
The first of these mechanisms is limited and the third is detrimental due to the adverse 
effects of chronic stimulation of the sympathetic nervous system.
Therefore a key compensatory mechanism is increasing muscle mass. The increase in 
muscle mass is caused by myocyte hypertrophy and alteration in the extracellular 
matrix. These mechanisms will be discussed in depth later.
The basis of hypertrophy can be explained by the law of Laplace, which defined the 
load on any region of the myocardium as a fimction of (pressure x radius)/ (2 x wall 
thickness).
Therefore it can be seen that any increase in pressure can initially be offset by an 
increase in wall thickness. The systolic stress is a major determinant of systolic 
ejection performance thus by normalising the systolic stress via hypertrophy this 
maintains normal systolic function. Thus LVH is initially an adaptive process and if 
this were to be perfectly regulated then a feedback loop would exist ensuring wall 
stress was constantly normalised however this does not appear to exist and chronic 
hypertrophy is undoubtedly deleterious.
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Pathogenesis.
The pathogenesis of left ventricular hypertrophy can be conveniently divided into 
myocyte hypertrophy and alterations in the extracellular matrix.
1:2:1 Myocyte Hypertrophy.
Cardiac myocytes account for 80% of tissue volume in the adult heart but only 
account for 35% of the cell number. In left ventricular hypertrophy the cardiac 
myocytes increase in length, width and volume.
During “compensated hypertrophy” the myocyte increases in volume however 
the length width ratio remains constant (Zierhut 1991). However during 
decompensation and progression to pump failure there is a dramatic increase in length 
width ratio and prolongation of the myocyte vrith loss of transverse growth (Gerdes 
1996). It is unclear the exact signalling mechanisms that are involved in regulating 
myocyte growth. It would appear that mechanical signals can be transmitted through 
collagenous struts to the myocyte (Bloom 1996). However cardiac hypertrophy 
differs greatly depending on pathogenesis e.g. pressure versus volume overload. With 
myosin heavy chain synthesis being upregulated early in pressure overload (Imamura 
T, 1994) whilst in volume overload myosin chain synthesis is decreased (Matsuo T 
,1998).
In pressure overload the myocytes hypertrophy results from the parallel addition of 
sarcomeres. Whilst m volume overload myocyte lengthening occurs by the addition of 
sarcomeres in series.
Both forms of hypertrophy are accompanied by changes in gene reprogramming 
(Swynghedauw, 1999).
These include the re-expression of immature foetal cardiac genes including;
1.Genes that modify motor unit composition and regulation.
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2.Genes that modify energy metabolism.
3.Genes that encode components of neurohormonal pathways.
The implication from these findings is that mechanical force is transduced into a 
biochemical event that modifies gene transcription. A candidate for this transducer is 
the focal adhesion complex.
1.3 The Extracellular Matrix.
Components of the extracellular matrix.
1.3.1 Cardiac Collagen.
Currently eighteen distinct collagen types have been identified. These are coded at 30 
separate genes. The relative abundance of the different collagens varies from tissue to 
tissue. The major interstitial collagens are type I, III and IV, which constitute over 
90% of, total cardiac collagen content. The interstitial collagens consist ofthiee 
polypeptide alpha chains composed of large helical domains. Each chain has a high 
hydroxyproline concentration that facilitates measurement of hydroxyproline as 
measure of collagen concentration. The precursor of both types I and III collagen 
contains three separate domains. Firstly the helical domain described above, secondly 
an N pro-collagen peptide domain and thirdly a globular C terminal region. On 
incorporation of the pro collagen into the established collagen hefix both the N 
terminal and C terminal are cleaved.
Type I and III collagens have very different structures and functional significance. 
Type I collagen forms rod like fibres providing tensile strength. Whilst, type III 
collagen forms a fine network of fibrils. The relative amounts of collagen type I and 
III vary with development and in the presence of pathological states.
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The other collagens present in the cardiovascular system represent a small proportion. 
Type IV and V are basement membrane proteins whilst collagen type VI is found 
coating collagen fibres in the interstitium.
Table 1.1 Cardiac Collagens
Major functionType Composition Location Origin
I
III
IV
V
Interstitium,
vessels
Interstitium
Vessels
Basement
Membrane
Interstitium
Vessels
F,S,E
f ,s ,e
F,S,E,M
f ,s ,e
VI Interstitium F,S
Vessels
Structural
Structural
cell attachment
Substrate filter
Structural
Cell-Cell
signalling
Structural
F= fibroblast s=smooth muscle celt, E= endothelial cell, M =myocyte
1.3.2 The collagen network
The normal collagen network consists of collagen type I and III. Types IV, V and VI 
are present but in far lesser amounts. The cardiac collagen network consists of an 
épimysium which surrounds large groups of muscle fibres. This is found beneath the 
endothelial cell lining of the endocardium. From the épimysium arises a perimysium 
consisting of coiled fibres and weave like structures that surround smaller groups of 
muscle fibres grouping them into parallel bundles. The perimysium forms a net within
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which the muscle fibres are organised which limits cardiac stretch. Finally an 
endomysium tethers individual muscle fibres together and connects adjacent 
micro vasculature. Individual fibres of the endomysium are connected to myocyte 
cytoskeletal proteins, which allow transmission of myocyte generated force. Fibrillar 
collagen preserves muscle fibre orientation and is responsible for maintenance of the 
cardiac architecture additionally preventing muscle slippage.
The extracellular matrix thus acts as scaffolding for the cardiac myocytes. The 
myocytes are arranged in series and parallel with elastic elements which are the 
fibrillar coUagens.
Collagen turnover. 
1.3.3 Collagen synthesis.
Collagen synthesis is a complex process involving several post transcriptional and 
post-translational steps. Pro-collagen genes code for the pro-alpha 1 and pro-alpha 2 
chains. The pro-alpha chains are then incorporated into triple helical pro-coUagen. 
Pro-hydoxylase then catalyses the hydroxylation of proline thus stabilising the helix. 
Disulphide bonds form linking the pro-alpha chains to the C terminal. Fibre formation 
essentially then forms a self-assembly process.
1.3.4 Collagen degradation.
Two main pathways of collagen degradation exist; intracellular degradation and 
extracellular degradation.
Intracellular degradation occurs in the lysosomes and fimctions to prevent the 
secretion of defective molecules and regulates production in response to extracellular 
stimuli.
Extracellular degradation is largely regulated by a family of zinc and calcium 
dependent endopeptidases called Matrix Metalloproteinases (MMPs). These
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endoproteinases share structural domains but differ in key features; namely, substrate 
specificity, cellular sources and inducibility. Currently more than twenty mammalian 
types have been identified. All MMPs share basic features.
1. They degrade extracellular matrix components.
2. They are secreted in a latent form and therefore require activation.
3. They contain an active Zn2+ site.
4. They require calcium for molecular stability.
5. They function at a neutral pH.
6. They are inhibited by a specific group of inhibitors called Tissue Inhibitors of 
Matrix Metalloproteinase.
The family of MMPs have been classified in several ways. The most helpful
method is using substrate specificity and molecular structure. Using this method
they can be conveniently be divided into four groups.
1. The CoUagenases. This includes MMPl (interstitial collagenase), MMP-8 
(neutrophil collagenase) and MMP-13 (coUagenase-3). This group can cleave 
fibrillar coUagens (types 1, II and 111). The fibriUar coUagens represent a 
particularly resistant group due to their apposed and cross Unked fibrUs and as 
such are resistant to almost aU other proteases. CoUagenases cleave fibriUar 
coUagen at a unique site in the triple helix % fi-om the N terminal resulting in 
% and Va coUagen fi*agments. This results in thermal degradation and loss of 
stabiUty with the ^fragments losing their characteristic and stable triple helix 
and forming single chain molecules caUed gelatins.
2. The Gelatinases. The two main gelatinises are MMP-2 and MMP-9 which are 
capable of degrading gelatins. In addition gelatinises are capable of degrading 
basement membrane coUagen type IV.
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3. The Stromeolysins. This includes MMP-3, MMP-10, and MMP-11. They have 
proteolytic actions against a broad range of extracellular matrix components 
including proteoglycans, laminins, fibronectin, vitronectin and some types of 
coUagens. This proteolytic system degrades a wide spectrum of extraceUular 
matrix proteins and is constitutively expressed in a number of ceU and tissue 
types.
4. Membrane bound MMP (MT-MMP). This group has been recently described 
and constitute a novel class for four main reasons. Firstly, they are membrane 
bound and hence constitute a focal area for proteolytic degradation. Secondly, 
MT-MMPs are proteolyticaUy active when inserted into the membrane and do 
not require further activation. (Murphy 1997, Miyamori 2000) Thirdly, they 
perform a key role in activation of other non membrane bound MMPs 
(Murphy, 1997) and finaUy TIMPs faU to bind effectively to MT-MMP and 
thus are unable to exert inhibitory control. (Miyamori, 2000)
MMPs play an essential role in normal tissue remodeUing however are also expressed 
and appear to play an important role in numerous pathological processes, for example 
plaque rupture (Galis, 1994), tumour angiogenesis (Nelson, 2000), metastasis 
(Nelson, 2000) and rheumatoid arthritis.
Table 1.2: The Matrix Metalloproteinases.
Enzyme MMP Human Chromosme
CoUagenases.
Interstitial collagenase: MMP-1 Hq22-q23
Collagenase 1.
Neutrophil Collagenase: MMP-8 Hq21-q22
Collagenase 2.
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Collagenase 3 MMP-13 llq22.3
Collagenase 4 MMP-18 NA
Gelatinases.
Gelatinase A MMP-2 16ql3
Gelatinase B MMP-9 20qll.2-ql3.:
Stromeolysins,
Stromeolysin 1 MMP-3 Ilq23
Stromeolysin 2 MMP-10 Hq22.3-q23
Stromeolysin 3 MMP-11 22qll.2
Membrane Type MMPs
Transmembrane.
MTl-MMP MMP-14 14qll-ql2
MT2-MMP MMP-15 15ql3-q21
MT3-MMP MMP-16 8q21
MT5-MMP MMP-24 20qll.2
GPI anchor
MT4-MMP MMP-17 12q24.3
MT6-MMP MMP-25 16pl3.3
Others
Macrophage elastase. MMP-12 llq22.2-22.3
No trivial name. MMP-19 12ql4
Enamelysin. MMP-20 llq22.3
XMMP. MMP-21 NA
CA-MMP. MMP-23 lp36.3
CMMP. MMP-27 Hq24
28
Epüysin. MMP-28 17q21.1
1.3.5 Regulation of MMP activity.
MMPs are potent and their proteolytic activity requires strict control. This can be seen 
to broadly occur at three levels.
1 .Transcriptional regulation. The expression of most MMPs occurs at low levels in 
most tissue however, is upregulated during certain physiological and pathological 
processes.
Numerous growth factors, inflammatory cytokines and hormones have been shown to 
induce or stimulate MMP synthesis. Interleukin I, platelet derived growth factor, 
Tumour necrosis factor-alpha, epidermal growth factor and basic fibroblast growth 
factor and CD40 have been shown to have stimulatory effects (Malik 1996, 
Schonbeck 1997). Whilst TGF beta, heparin and corticosteroid have been shown to 
have inhibitory effects on MMP gene expression (Wassenaar 1999). Not all MMPs 
react similarly to these factors.
2.Proenzyme activation. One of the characteristics of MMPs is that they are secreted 
in an inactive proenzyme form (with the exception of membrane bound MMPs) and 
so they require activation in order to have any effect on the extracellular matrix.
Three different activation mechanisms are present. Firstly, stepwise activation. 
Secondly, activation at the cell surface by MT-MMPs and thirdly, intracellular 
activation (Nagase 1997). The first stage in stepwise activation usually involves a 
proteinase, of which plasmin appears to be the most important (Murphy 1994). 
Plasmin attacks the proteinase susceptible region of the MMP inducing 
conformational changes, which renders the activation site susceptible to cleavage by a 
second proteinase, which is usually a second MMP (Nagase 1997). The generation
29
of plasmin from plasminogen activators occurs at the cell surface where both 
plasminogen and urokinase activators are bound. The roles of urokinase plasminogen 
activator (uPA) and its specific inhibitor uPA receptor (uPA-r) in addition to Plasmin 
activator inhibitor I and II have been shown to have central roles. Binding to uPA 
localises proteolytic activity whilst expression of uPA-r on macrophages and 
monocytes prevent degradation. (Kircheimer, 1989, Estreicher, 1989) A positive 
feedback mechanism appears to exist whereby active enzymes activated other 
proenzymes resulting in a fivefold to eightfold increase in proteolytic activity.
CeU surface activation of MMPs is important in the periceUular degradation of the 
ECM during ceU migration. In addition to the plasminogen system MT-MMPs play an 
important role in ceU surface activation (Sato 1994).
The precise mechanism of intraceUular activation has not been identified.
3.Direct Inhibitors of MMPs. The main inhibitors of the MMPs are alpha- 
macroglobulin, which is restricted by its large size and a family of specific inhibitors 
caUed Tissue inhibitors of Matrix MetaUoproteinases.
Figure 1.1 : Activation of Pro-MMPs
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1.3.6 Tissue inhibitors of Matrix MetaUoproteinases (TIMP).
A balance between the proteolytic activity of MMPs and their inhibitors, TIMPs, is a 
prerequisite for normal tissue function. The TIMP family consists of at least four 
distinct members, which possess 12 conserved cysteine residues and express MMP 
inhibitory activity. TIMPs are expressed by a variety of cell types and are present in 
most tissues and body fluids. TIMP-1 and TIMP-2 are present in soluble form whilst 
TIMP-3 is insoluble and bound to the extracellular matrix.
Structure and Function.
The four characterised members of the TIMP family share several structural features.
1. They all possess 12 cysteine residues in conserved regions of the molecule 
forming six disulphide bonds.
2. The NH2 terminal domain is necessary for the MMP inhibitory activity. All 
four TIMPs share a consensus sequence (VIRAK) in this domain.
3. A 29 amino acid sequence is cleaved off to produce the active, mature protein. 
TIMP-L
TIMP-1 was originally isolated from rabbit bone and characterised as an inhibitor of 
collagenase activity. (Sellers A, 1977) Human TIMP-1 was purified and obtained 
from amniotic fluid (Murphy G, 1981) and skin fibroblasts. (Striklin G 1983) The frill 
protein sequence was ultimately described by Carmichael and co-workers. 
(Carmichael DF 1986). TIMP-1 is produced and secreted by a variety of cells and 
widely distributed throughout the body (Cawston 1986). The TIMP-1 molecule 
consists of 184 amino acids. This includes the 12 cysteine residues, which form six 
disulphide bonds that hold together the six loops and divide the molecule into three 
knot-bke structures (Docherty 1985). Depending on glycoslylation the molecular
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mass extends from 20kDa to 40kDa. The NH2 terminal domain appears to be central 
to the MMP inhibitory function of the TIMP-1 molecule (Murphy 1991).
TIMP-2
TIMP-2 is a 21kDa unglyosylated protein first described by three separate groups in 
1989(DeClerck 1989, Goldberg 1989, Stetler-Stevenson 1989). TIMP-2 shares 40% 
amino acid identity with TIMP-1 (Stetler-Stevenson 1989) and possesses six 
disulphide bonds in the same conserved positions (DeClerck 1989). The N terminal 
domain is once again necessary for the MMP inhibitory action (DeClerck 1993). 
TIMP-3
TIMP-3 is an insoluble 21kDa unglycosylated protein, which was, originally purified 
form chicken embryo fibroblasts (Pavloff 1992). The human molecule was detected in 
WI-38 fibroblasts (Wick 1994) and shares 30% sequence homology with TIMP-1 and 
38% homology with TIMP-2 (Pavloff 1992). TIMP-3 possesses exclusive properties 
that differentiate it clearly from the other members of the TIMP family. Namely, that 
it is restricted to the extracellular compartment (Pavloff 1992) and it induces 
apoptosis when over-expressed in certain cell types (Ahonen 2003, Bond 2002). The 
mechanism by which TIMP-3 induces cell death is not clear however evidence 
suggests a link with death receptor-mediated apopto sis(Ahonen 2003, Bond 2002). 
TIMP-4
TIMP-4 has been most recently identified by molecular cloning (Greene 1996). It is 
highly expressed in the heart in comparison with other tissues. It appears to share 37% 
sequence homology with TIMP-1 and 57% with TIMP-2 and TIMP-3 (Greene 1996).
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1.3.7 MMP inhibition and ECM turnover.
TIMPs inhibit MMP activity through high affinity, irreversible, non-covalent binding 
of the active forms of MMPs at molar equivalence (Murphy 1995). As discussed 
above, studies have previously shown that the NH2 terminal domain is important in 
the MMP inhibitory role of the TIMP molecule. A C-terminally truncated form of 
TIMP-1 comprising only of the N terminal has been shown to inhibit MMP-3 with 
only a slightly reduced aflSnity in comparison with the full length TIMP-1 (Murphy 
1991). However, more recent work has the demonstrated that the structural 
relationship between TIMP-1 and MMP-3 is much more complex. Gomis-Ruth et al 
(1997) described the complex formed between unglycosylated TIMP-1 and the 
catalytic domain of MMP3 using an X-ray crystal structure analysis. This revealed 
that TIMP-1 had the shape of an elongated wedge, which occupied the entire length of 
the active-site cleft of MMP-3. Of the six separate polypeptide segments of TIMP-1, 
which were involved in the complex, four were provided by the N terminal and two 
by the C terminal. Demonstration of this unusual architecture will aid the design of 
future synthetic MMP inhibitors.
TIMPs act on a broad range of MMPs. TIMP-1 potently inhibits the activity 
of most MMPs with the exception of MMP-2 and MTl-MMP. However the actions of 
TIMP-1 are more complex than merely the inhibition of active MMP molecules. For 
example, TIMP-1 can also bind to the proform of MMP-9. The consequent molecule 
pro-MMP-9/TIMP-l can inhibit active MMP forming a more stable complex pro- 
MMP-9/TIMP-1/MMP (Kolekenbrock 1995). TIMP-2 is a potent inhibitor of MMPs 
with the exception of MMP-9. Additionally TIMP-2 has a dual inhibitory action, 
binding to progelatinase A (pro-MMP-2) (Goldberg 1989). It has been shown that the
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pro-MMP-2/TIMP-2 complex prevents autoactivation of MMP-2 and that the binding 
of TIMP-2 to the active form of the enzyme has a stabilising effect (Howard 1991). It 
can also form a complex with MTl-MMP at the cell membrane, which may play a 
regulatory role in the proteolytic activation of MMP-2.
TIMP-3 is limited to the extracellular compartment and has been shown to bind to 
MMPl, 2,3,9 and 13 in the extracellular matrix.
TIMP-4 inhibits MMP 1,3,7 and 9 and shows a high level of expression in adult 
human cardiac tissue.
Regulation.
TIMP-2 expression is largely constitutive, following the pattern of expression of 
gelatinase A with which it interacts specifically. Whereas, TIMP-1 expression is 
highly inducible by a variety of cytokines and hormones. TIMP-1 has shown in some 
studies to be co-ordinately regulated with MMPs and in others reciprocally regulated. 
Factors such as phorbol esters and interleukin-IB stimulate both TIMP-1 and MMP 
expression (Overall 1994). Whilst MMPs are downregulated and TIMPs stimulated 
by factors such as TGF-beta (Overall 1991).
Reported actions o f TIMP-1.
Whilst I have concentrated on the role of TIMP-1 in extracellular matrix remodelling 
TIMP-1 has been shown to be active in numerous conditions listed in tabular format 
below.
Table 1.3: Reported actions of TIMP-1.
Reported actions of TIMP-1
Role in embryonic bone tissue remodelling. (Hill 1993)
Role in gonadal steroidgenesis. (Boujrad 1995)
Role in ovulation, pregnancy, and parturition. (Jeffrey 1991)
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Inhibits tumour cell invasion and metastasis in experimental models. (DeClerck 1992) 
Associated with advanced tumour stage of non-Hodgkin’s lymphoma. (Kossakowska 
1991)
Modulation of vascular injury. (Webb 1997, Dollery 1999)
1.4 Functional significance of the extracellular matrix.
The extracellular matrix has a key role in a normal fimctioning myocardium.
1. It provides sarcomere alignment and ensures the structural integrity of adjoining 
myocytes.
2. It provides the means by which myocyte shortening is translated into ventricular 
pump function.
3. It prevents “myocyte slippage”
4. It is essential for maintaining the alignment of myofibrils within the myocytes.
1.5 Structural Remodelling in Hypertensive Heart Disease.
Myocyte hypertrophy has been described above. In addition to myocyte hypertrophy 
there is an intensive interstitial fibrosis resulting in a qualitative as well as a 
quantitative alteration in the myocardial structure. The fibrosis has several distinct 
morphological presentations. (Anderson 1979, Pearlman 1982, Huysman 1989) It 
occurs around the intramyocardial coronary arteries ands arterioles where it represents 
a perivascular fibrosis. From the perivascular space it extends in to the interstitial 
space producing an interstitial fibrosis. This is a progressive process involving 
increasing amounts of the interstitium and resulting in distortion of the normal 
myocardial architecture (Silver 1990). This is a primary reactive process and can be 
seen throughout the pressure overloaded left ventricle and the normotensive right 
ventricle (Pearlman 1982). The demonstration of interstitial fibrosis in the
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normotensive right ventricle is a key finding and demonstrates that this process is not 
purely a load dependent phenomena. As the fibrosis progresses individual muscle 
fibres become encircled by thickened collagen fibres resulting in muscle atrophy (Jalü 
1991).
Distinct fi-om this reactive fibrosis a reparative process also occurs resulting in a 
fibrous “patch” which bridges the gap left by myocyte necrosis. This “patch” consists 
of thick collagen fibres, which join adjacent muscle fibres, and through this thin 
collagen fibres can be seen to entwine forming scar tissue. The mechanism 
responsible for myocyte necrosis is unclear, however there are two proposed 
mechanisms. Firstly it may be initiated by the initial reactive interstitial fibrosis 
described above, through direct “ strangulation” of the muscle fibres or interference 
with normal myocyte nutrition by increasing the distance between capillary beds and 
the myocytes thus affecting oxygen difiusion. Secondly, this phenomena may not 
represent myocyte necrosis but in fact represents myocyte apoptosis which has been 
demonstrated to be an important regulatory mechanism in response to pressure 
overload (Teiger 1996).
1.5.1 Factors controlling structural remodelling.
Haemodynamic Factors
Several clinical observations and some in-vitro work suggest haemodynamic overload 
plays a role in the development of fibrosis. Tanaka et al (1986) demonstrated that the 
collagen volume fraction increases from the outer to the inner third of the LV free 
wall in postmortem hypertensive hearts. Which may reflect transmural gradients of 
wall stress. Furthermore Querejeta et al (2000) demonstrated some relationship 
between severity of LVH and severity of fibrosis on myocardial biopsy. Finally, in-
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vivo studies have shown that procollagen type I synthesis is stimulated in cardiac 
fibroblasts submitted to mechanical load (Bishop 1999).
Non-haemodynamic Factors.
There are several features, which demonstrate that non-haemodynamic factors have a 
key role in the development of interstitial fibrosis. Firstly, fibrosis is seen in the 
normotensive right ventricle, secondly, conditions that result in hypertension but not 
activation of the renin angiotensin system do not result in fibrosis (Brilla 1990) and 
finally regression of fibrosis is independent of antihypertensive effect (Brilla 2000). 
These concepts will be examined in detail below.
The effector hormones of the renin angiotensin system are central to the control of the 
development of fibrosis. The animal models described below allow the manipulation 
of the renin angiotensin system and subsequent pathological examination of the 
structural myocardial changes.
Using the rat model, stimulation of the renin angiotensin system can be achieved by 
surgically induced unilateral renal ischaemia or by supra-renal aortic banding. Both 
these models result in an increase in circulating angiotensin II and aldosterone levels. 
Studies using these models have demonstrated fibrosis of both the hypertensive 
hypertrophied left ventricle and the normotensive non-hypertrophied right ventricle. 
(Doering 1988, Jalil 1988, Brilla, 1990, Lindy 1972) The interstitial fibrosis in this 
model can be prevented by the administration of Captopril. (Jalil 1991) This 
implicates a role in the development of fibrosis for circulating effector hormones of 
the renin angiotensin system.
This is fiirther confirmed when we examine models of hypertensive heart disease 
which result in sustained hypertension but not in activation of the renin angiotensin 
system, namely infra-renal banding. Pathological analysis of this model reveals that
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neither a reactive or reparative fibrosis occurs despite sustained hypertension (Brilla 
1990).
Furthermore models of volume overload hypertrophy such as A-V fistula (Weber
1990), chronic anaemia (Bartosova 1969), atrial septal defect (Marino 1985) and 
chronic thyroxine administration (Bartosova 1969) which result in hypertrophy but 
not activation of the renin angiotensin system again do not show a reactive or 
reparative fibrosis.
The role of Angll and aldosterone was fiirther addressed by studies, which involved 
the chronic infusion of ang II and aldosterone in subpressor doses. (Sun 1993, Tan
1991) Individually both angll and aldosterone models resulted in fibrosis 
characterised by both microscopic scar formation and a primary reactive perivascular 
fibrosis. (Sun 1993)
Other factors are also clearly important in the development of fibrosis. If we look at 
models of mineralocorticoid excess with suppressed plasma renin and Angiotensin II 
concentrations then again there is clear evidence of fibrosis (Brilla 1990). This can be 
prevented by the addition of spironolactone in doses, which did not affect the blood 
pressure (Brilla 1993). Spironolactone and amiloride have been shown to prevent the 
formation of microscopic scars and by extrapolation prevent myocyte necrosis in 
hypertensive rats treated with Aldosterone. (Campbell 1993, Brilla 1992)
Dietary KCL supplementation has been shown to have similar cardioprotective effects 
probably secondary to the role intramyocardial potassium depletion plays in myocyte 
loss and subsequent scar formation. (Darrow 1942)
From the findings of the animal models described above we can conclude;
1. Perivascular and interstitial fibrosis is associated with chronic elevations in the 
effector hormones of the renin angiotensin system.
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2. Perivascular and interstitial fibrosis is independent of arterial hypertension and 
myocyte hypertrophy.
3. Reparative fibrosis following myocyte necrosis is associated with elevations in 
plasma angll and to intramyocardial potassium depletion secondary to chronic 
mineralocorticoid excess.
1.5.2 Mechanisms of Fibrosis.
As we have established the central role played by the renin angiotensin system in the 
development of fibrosis, the mechanisms by which this is effected should be 
examined. Factors responsible for the appearance of the perivascular and interstitial 
fibrosis include;
1. Hormonally mediated coronary vascular hyperpermeability.
2. Direct hormonal regulation of fibroblast collagen turnover.
3. Autocrine and paracrine signalling that takes place between cells.
Hormonally mediated coronary hyperpermeability.
Reddy et al demonstrated that an acute elevation in plasma Angll created by a pressor 
dose of intravenous Ang II was associated with an increase in coronary vascular 
permeability and the subsequent appearance of macromolecules in cardiac lymph. 
(Reddy, 1995). This contrasted with a model, which produced hypertension 
independently of angll (intravenous Methoxamaine), which did not show changes in 
cardiac lymph. In this study, coronary sinus pressure was increased to create a 
filtration-independent state in both models. Reedy concluded that angll produces an 
increase in coronary permeability independent of hypertension or venoconstriction. 
Sun et al (1993) clarified this situation by using sub-pressor doses of angll and 
observing the sequence of events that resulted in fibrosis. He reported the appearance
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of fibronectin (a macromolecule several times the size of albumin) within the 
interstitial space within 24-48hours. Proliferating fibroblast were seen in the 
interstitium within 2-4 days followed by enhanced expression of type I mRNA and 
increased collagen type I synthesis. This sequence of events was present in both 
ventricles.
Thus perivascular fibrosis, which occurs in the context of elevations in plasma angll 
and in the absence of hypertension, is associated with macromolecular 
hyperpermeability. The contribution of macromolecular hyperpermeability excluding 
the other pro-fibrotic effects of angiotensin II in the resultant fibrosis cannot be 
determined by these studies.
Hormonal regulation of fibroblast turnover.
The cardiac fibroblast is responsible for collagen turnover in the myocardium. It is 
responsible for transcription and deposition of type I and III coUagens and also for the 
transcription of matrix degradative metaUoproteinases and their inhibitors. Therefore 
it plays a key role in the development of fibrosis. CeU surface receptors for 
angiotensin II, aldosterone and endothelin have been identified on the cardiac 
fibroblast. The effects of the effector hormones of the renin angiotensin system on 
cardiac fibroblasts have been studied.
Angiotensin II.
CoUagen synthesis of adult rat cardiac fibroblasts has been to shown to increase in a 
dose dependent manner by the administration of angiotensin II. (BriUa, 1994) This 
response is mediated through the type I receptor subtype. (BriUa, 1994) The type II 
receptor subtype appeared to mediate a reduction in coUagenase activity in fibroblast
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culture. (Brilla, 1994) Furthermore, in mice with aortic banding, the type II receptor 
subtype mediated an inhibitory effect on remodelling (Akishita 2000).
Aldosterone.
Aldosterone increased fibroblast collagen synthesis in a concentration dependent 
manner, which could be prevented by the administration of the aldosterone antagonist 
spironololactone. There was no effect on collagenase activity. (Brilla, 1994) 
Endothelins.
Endothelin I and Endothelin 3 have been shown to increase collagen synthesis in a 
concentration dependent manner. Both Eta and Etb receptors were involved. (Guarda, 
Katwa, 1993) Collagenase activity was reduced by ET-1 but not ET-3 and this effect 
could be blocked by an antagonist to the subtype A receptor. (Guarda, Katwa, 1993) 
Cell-cell signalling and local regulation of collagen turnover.
Endothelial cell-derived signals.
Endothelial cells produce substances, which can act as promoters or inhibitors of the 
growth and behaviour of neighbouring non-endothelial cells such as fibroblasts. 
Guarda et al addressed the effects on fibroblast collagen turnover by endothelial cells. 
He demonstrated that endothelial cell-conditioned media was found to increase 
fibroblast collagen synthesis and to increase collagenase activity. This did not appear 
to be dependent of angll or aldosterone as their respective antagonists did not prevent 
this response neither did the addition of angll or aldosterone augment the fibrosis. 
(Guarda,Myers, 1993)
Tissue receptors.
An autocrine or paracrine system requires the presence of receptors in tissue and that 
theses receptors be fimctionally active in response to locally generated or circulating 
signals.
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In-situ hybridisation has demonstrated the presence of receptors for angiotensinogen 
on cardiac fibroblasts 
Nonendotheial tissue ACE.
Using in-vitro autoradiography together with an iodinated tyrosyl derivative of 
Lisinopril Sun et al have demonstrated a nonendothelial tissue angiotensin-converting 
enzyme (TACE) that was localised to tissues rich in active fibroblasts and fibrillar 
collagen. TACE binding was found in high density in myocardial scar formation and 
the fibrosis surrounding intramyocardial vessels. (Johnston, 1991, Sun 1993) TACE 
binding density was found to be independent of circulating renin and angiotensin. 
(Schunkert, 1993) TACE appears to be an integral feature of fibrous tissue formation 
and itself represents a marker for fibrosis. It may regulate local concentrations of 
angll and bradykinin.
Angiotensin II and aldosterone receptors.
In order to determine whether angll and aldosterone receptors were present in fibrous 
tissue Sun et al used quantitative in vitro autoradiography. (Sun, Weber, 1993) 
Myocardial fibrosis was induced with chronic administration of angiotensin or 
aldosterone. Receptors for both Aldosterone and AT-1 were found in the normal rat 
myocardium. However the perivascular fibrosis and scarring of the ventricles seen 
with angll or aldosterone administration was not anatomically coincident with the 
presence of angll or aldosterone receptors. This may suggest that angll or aldosterone 
may not directly influence fibrous tissue formation but may in fact act through the 
release of other mediators such as ET-1 or cytokines such as TGF-beta.
Bradykinin Receptors.
Bradykinin is a substrate for ACE and the presence of bradykinin receptors was 
examined by Sun et al using a rat model infiised with angll or aldosterone. (Sun,
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Weber, 1993) Bradykinin receptors were identified in the perivascular fibrosis and 
endomyocardial scarring seen in each ventricle. These receptors, unlike angll and 
aldosterone were anatomically coincident with ACE binding. Thus, fibrous tissue 
ACE appears to fimction as a kinase regulating local concentrations of bradykinin.
1.6 Biochemical monitoring of myocardial fibrosis.
Cardiac biopsy is undoubtedly the gold standard for assessment of myocardial 
fibrosis. However this procedure does have appreciable complication rate and is both 
inconvenient and uncomfortable for the patient. Therefore a non-invasive means of 
monitoring the process of fibrosis is undoubtedly an attractive one.
Measurement of biochemical markers of collagen synthesis, degradation and 
inhibition of degradation holds promise in this regard.
1.6.1 Biochemical Assessment of Collagen Type I Synthesis and Degradation.
Collagen type I is synthesised in fibroblasts as a procollagen precursor. This 
contains an N and a C terminal. When the procollagen is being integrated into the 
collagen helix propeptides are removed by a variety of proteinases leaving the 
collagen molecule to be integrated. (Nimmi, 1993) The 100 kDa procoUagen type I 
carboxyterminal propeptide (PI CP) is cleaved fi-om the procollagen type I during the 
synthesis of fibril-forming collagen type I. A stoichometric ratio of 1:1 exists between 
the number of collagen type I molecules produced and the number of PI CP released. 
PI CP is cleared by the liver. (Smedrod, 1990)
The rate-limiting step in degradation is the cleavage of coUagen type I fibrils 
by interstitial coUagenase. (Janicki 1995) This enzyme is active at a specific locus and 
cleaves aU three alpha chains of the coUagen. This results in a 36kDa and a 12kDa 
telopeptide. The larger telopeptide spontaneously denatures. The smaU 12kDa
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pyrindinoline cross-linked carboxyterminal telopeptide of collagen type I (CITP) 
remains intact. This is released in a stoichometric 1:1 fashion. ( Ristelli, 1993)
Therefore PI CP can be seen as a potential marker of collagen synthesis and 
CITP as a marker of collagen degradation.
PI CP and CITP can be measured directly using commercially available 
radioimmunoassays.
Experimental studies.
Diez et al have performed the majority of experimental studies. They studied 
spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) by means of 
myocardial biopsy and quantitative analysis of the collagen content. Untreated SHR 
rats showed an interstitial and perivascular fibrosis and an increase in collagen 
volume fi-actions. In addition to the pathological analysis, serum PI CP and CITP were 
measured. Both PI CP and CITP were elevated and serum PI CP was found to directly 
correlate with pathological indices namely collagen volume firaction. (Diez, 1996, 
Varo, 1999, Varo, 2000)
Subsequent experiments compared untreated SHR with SHRs treated with 
Quinapril (Diez, 1996) and Losartan. (Varo, 1999 and Varo, 2000) There was a 
marked reduction in fibrosis in the treated rats and this was associated with decreased 
PI CP and a tendency to increased CITP concentrations. This effect was seen at doses 
that did not result in blood pressure reduction. (Varo, 2000)
Clinical Studies.
Diez et al have looked at PI CP and CITP concentrations in untreated patients 
with essential hypertension. (Diez, 1995, Laviades, 1998, Laviades, 2000)
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Measurements were repeated after treatment with an ACE-inhibitor (Lisinopril) or an 
Angiotensin II antagonist (Losartan).
Baseline measurements of PI CP were significantly higher amongst the 
hypertensive group when compared with a cohort of normal subjects. CITP levels 
were not significantly different. Serum PI CP levels were found to correlate with left 
ventricular mass and the severity of ventricular arrhythmias. (Diez, 1995)
Treatment of patients with Lisinopril or Losartan resulted in regression of 
LVH, normalisation of diastolic filling, reduction in PI CP and elevation in CITP.
Studies utilising transvenous endomyocardial biopsies and estimation of 
collagen volume fi-action (CVF) have demonstrated correlations between PI CP and 
CVF in an untreated hypertensive cohort (Querejeta 2000) and following treatment 
(Lopez 2001).
Summary
These studies suggest: 1. Collagen metabolism is abnormal in rats and humans 
with untreated hypertension. 2.Serum concentrations of PI CP and CITP may be of 
use for the non-invasive assessment of fibrosis in patients with untreated 
hypertension. These studies are undoubtedly of interest and lay the foundation for 
human studies of non-invasive assessment of myocardial fibrosis in untreated 
hypertension.
1.6.2 Biochemical assessment of Inhibition of Degradation.
As previously described Tissue Inhibitors of Matrix MetaUoproteinases provide the 
central means of regulating MMP activity and consequently coUagen degradation. 
Thus measurement of TIMP-1 levels would provide a non-invasive means of
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assessing collagen degradation. TIMP-1 levels can be measured using a commercially 
available two stage ELISA assay. The technique used is a modification of the original 
reported by Plumpton (1995).
Laurent et al (1978) proposed that an equilibrium exists between collagen synthesis 
and degradation in normal tissue. This equilibrium is disturbed during pathological 
states, which result in fibrosis. Increasingly the role of TIMPs has been assessed in 
this equilibrium. Clearly, an important mechanism for the development of fibrosis 
may be inhibition of collagen degradation leading to fibrosis. Several studies have 
pointed towards this as a potential mechanism. Diez et al (1996) demonstrated in 
spontaneously hypertensive rats that collagen synthesis is increased however collagen 
degradation is unchanged. Furthermore BriUa et al (1994) reported that MMP-1 
activity is abnormaUy reduced in hypertensives with LVH. The conclusion reached by 
these groups was that the intensity of coUagen degradation is not sufficient to offset 
the increment in coUagen synthesis and thus results in fibrosis. A possible mechanism 
for this would be an abnormal increment in TIMP activity.
Laviades et al (1998) attempted to confirm this hypothesis using serum 
markers of coUagen degradation (CITP, MMP-1) and inhibition of coUagen 
degradation (TIMP-1). They studied a smaU number of patients with essential 
hypertension before, and after treatment with LisinoprU. They demonstrated increased 
levels of TIMP-1 in untreated hypertensive patients, reduced levels of MMP-1 and 
normal levels of CITP. After treatment with Lisinopril MMP-1 levels increased and 
TIMP-1 levels decreased with treatment. These findings aUowed Diez et al to 
hypothesise that coUagen degradation is depressed in untreated hypertension and that 
elevated TIMP-1 may mediate this process. There are, however, several flaws in this 
study. Firstly, smaU numbers of patients were studied in each group. Secondly, the
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authors analysed serum levels of TIMP-1, which have been shown to be inaccurate 
and inferior in comparison to plasma levels (Jung, 1997) probably due to the release 
of TIMP-1 during platelet activation (Copper 1985). Finally, despite demonstrating a 
reduction in MMP-1 and an increment in TIMP-1 the authors failed to demonstrate 
any material difference in actual degradation i.e. CITP levels. Nonetheless we found 
the hypothesis persuasive and this provided the stimulus to much of our work in 
patients with untreated hypertensives.
1.7 Clinical Consequences of fibrosis.
1.7.1 Reduced coronary reserve.
It is now recognised that patients with hypertensive heart disease have symptoms and 
signs of myocardial ischaemia despite having angiographically normal epicardial 
coronary arteries. This is related to impaired coronary flow reserve. (Houghton, 1990) 
There are many factors involved in the development of impaired coronary flow 
reserve however undoubtedly periarteriolar fibrosis plays a role. This has been 
demonstrated by Schwartzkopff et al who reported that the perivascular collagen 
fraction correlated with coronary resistance and reduced coronary flow reserve. 
(Schwartzkopff, 1993) In addition he demonstrated that treatment with ACE-inhibitor 
resulted in regression of the fibrosis and improvement in the coronary reserve. This 
was demonstrated in the absence of any change in media hypertrophy.
(Schwartzkopff, 2000)
1.7.2 Ventricular Arrhythmias.
LVH is associated with both an increase in sudden death and in ventricular 
arrhythmias assessed by Holter monitoring (Levy 1987, Malerba 1991, Messerli
47
1984). This has demonstrated an increased frequency and complexity of ventricular 
ectopy in patients with LVH (Messerli 1984, McLenechan 1987). However no clear 
relationship between these dysrhythmias and sudden death has been demonstrated.
Animal studies have revealed multiple electrophysiological abnormalities 
which may help to explain the incidence of arrhythmias in hypertensive patients. 
These include increased vulnerability to ventricular arrhythmia (Shechter 1989), 
dispersion of monophasic action potential duration (Kowey 1991) and refractoriness 
and action potential prolongation (Aronson 1980). Despite this wealth of laboratory 
data and observational studies, there is no direct experimental evidence that 
demonstrable ventricular ectopy leads to complex ventricular arrhythmias and 
consequent sudden death. Indeed studies using both late potential and invasive 
electrophysiological stimulation have failed to show any increment in the propensity 
for the inducement of re-entrant ventricular dysrhythmias (Pringle 1992).
1.7.3 Diastolic Dysfunction.
Diastolic Function.
1.7.3.1 Definition.
Diastole is defined as the time period from the closure of the semilunar valves until 
the closure of the atrioventricular valves. Put more simply, using the left ventricle as 
an example, diastole therefore consists of the time period between the aortic valve 
closure until the mitral valve closure.
1.7.3.2 Physiology of diastole.
Diastole is a complex energy dependent process involving the interplay of numerous 
factors. Attempts have been made to simplify this process by arbitrary division and 
further classification.
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This is based on the premise that diastole essentially consists of four events.
1. The isovolumic relaxation period. This period extends from the closure of the 
aortic valve until the opening of the mitral valve. The ventricular pressure declines 
without any change in the ventricular volume. Using a standard pressure volume 
curve this period can be seen to coincide with the descending limb.
2. The rapid filling period. This occurs following opening of the mitral valve. Due to 
the transmitral pressure gradient there is considerable passive filling. In normal 
circumstances passive filling accounts for up to 80% of ventricular filling.
3. The slow filling period. This period is also known as diastasis and consists of 
passive filling, which persists despite equalisation of chamber pressures due to 
momentum of the preceding phase of rapid atrial filling.
4. Atrial filling. This consists of atrial systole and accounts for around 15% of 
diastolic filling in a normal subject.
Left ventricular filling can therefore be seen to be central to the diastole. The two 
major determinants of which are 1. Ventricular relaxation. 2 “Effective chamber 
compliance”.
Ventricular relaxation begins mid systole continuing into the first third of diastole. It 
is an energy dependent process during which the contractile proteins are deactivated 
and the myofibrils return to their normal length.
The effective chamber compliance can be seen as the passive properties of the left 
ventricle as blood enters the ventricle during diastole. This description simplifies the 
complex interplay, which occurs to define the “passive” properties of the ventricles 
with interaction of ventricular relaxation, diastolic suction, passive filling, pericardial 
restraint and the viscoelastic forces of the myocardium.
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1.7.3.3 Assessment of diastolic function.
The complexity of diastolic function means accurate reproducible measurement will 
be difficult. Several methods have been employed.
Initially diastolic function was assessed using the measurement of the time constant of 
left ventricular decay (tau). This required haemodynamic and angiographic 
measurement at cardiac catheterisation. (Mirsky 1990) However this method is clearly 
not suitable for serial measurements and does carry a morbidity risk.
Digitised M Mode techniques have been used consisting of left ventricular M modes 
with simultaneous LV pressure tracings. This allows construction of pressure volume 
loops and calculation of measures of diastolic filling. (Gorscan 1994) However the 
major drawback to this technique is that the results are flawed in the presence of any 
wall motion abnormality.
Radionuclide angiography has also been employed with variable success. (Magorien 
1984)
Doppler assessment of diastolic filling.
Doppler assessment of diastolic filling is the most commonly employed method. It 
concentrates on the mitral flow derived doppler. The mitral flow velocity curves 
obtained correlates well with accepted methods such as digitised M-Mode 
echocardiography, radionuclide angiography and left ventricular angiography. 
(Friedman 1986) (Spirito B 1986)
The mitral valve velocity curves obtained with doppler should be seen as 
representative of the relative forces across the mitral valve. In the same way measured 
peak velocity is representative of instantaneous pressure change between the left
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atrium and the left ventricle. An understanding of this allows the mitral flow velocity 
curves to be interpreted in context with diastolic function. When contraction ceases 
the left ventricular pressure rapidly decays. When this pressure becomes less than the 
left atrial pressure the mitral valve opens and blood flows from the left atrium to the 
left ventricle on the pressure gradient created. A process of diastolic suction caused by 
further LV relaxation further enhances this gradient. This rapid blood flow is seen on 
the mitral doppler as the E wave. As the left ventricular pressure rises the transmittal 
gradient falls and ultimately equalises. This results in deceleration in the transmittal 
flow velocity curve. The rate at which the pressure gradient decreases determines the 
deceleration rate and deceleration time of the mitral E velocity curve. This is named 
the E wave deceleration time or DT.
During mid diastole there is equilibration of forces between the left atrium and the left 
ventricle however flow continues to fill the left ventricle due to inertial forces.
Finally atrial systole occurs with an associated reacceleration on the transmitral 
velocity curve called the A wave.
It is the assessment of this curve which gives an estimated of diastolic fimction.
The LA pressure, LA compliance, left ventricular diastolic pressure and the rate of 
ventricular relaxation, determines the peak E wave velocity. E wave deceleration is 
dependent on the rate of increase in the left ventricular pressure and is a measure of 
left ventricular compliance.
The A velocity is dependent on left ventricular chamber compliance as well as the 
volume and compliance of the left atrium.
The time from the elosure of the aortic valve until the onset of mitral flow is called 
the isovolumic relaxation time (IVRT) and is an additional measure of LV relaxation.
51
1.7.3.4 Factors affecting normal transmitral flow velocity curves.
1. Age. There are undoubted changes in diastolic filling secondary to the ageing 
process. These have been well documented and in practical terms consist of i) a 
reduction in E wave velocity, ii) an increase in A wave velocity iii) a prolongation 
in the E wave deceleration time and isovolumic relaxation time. (Spritito 1988)
2. Heart rate. With increasing heart rate there is fiision of the E and A waves with a 
consequent reduction in diastasis. There is an associated increase in A wave 
velocity. (Yamamoto 1993)
3. Preload. (Choong 1988)
4. Afterload. (Choong 1988)
1.7.3.5 Normal and abnormal filling patterns.
1 Abnormal Relaxation.
Abnormalities in left ventricular relaxation result in characteristic changes. Firstly due 
to impaired left ventricular relaxation there is a reduction in the rate of fall of left 
ventricular pressure with a consequent fall in transmitral gradient and a consequent 
reduction in mitral E wave velocity. There is an associated prolongation of the 
isovolumic relaxation time and the E wave deceleration time. Finally due to the 
aforementioned abnormalities there is augmentation of atrial contraction manifest by 
an increase in the A wave velocity 
Pseudonormalisation.
Interpretation of the doppler mitral flow velocity curves is made more difficult by the 
occurrence of pseudonormalisation which means that doppler assessment may on 
occasion be misleading. As ventricular compliance is reduced the left atrial pressure 
ultimately rises to compensate for this resulting in an increased early transmitral
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gradient. This results in a shortened isovolumic relaxation time, increased E wave 
velocity, reduced E wave deceleration time and a reduction in A wave velocity. Thus 
although there is significant impairment of left ventricular relaxation and a reduction 
in compliance the mitral flow velocity curve can appear essentially normal.
Restrictive pattern.
As impairment of ventricular compliance progresses the left atrial pressure increases 
as a consequence. This results in a “restrictive” pattern which is characterised by an 
increased E: A ratio (often greater than 2) and a marked reduction in isovolumic 
relaxation time and E wave deceleration time.
Differentiating between a normal filling pattern and pseudonormalisation is difficult. 
Clearly serial measurements will allow monitoring of the development of the patterns 
described however a one off study will not allow this. Examination of the pulmonary 
vein flows may help to distinguish. In pseudonormalisation the pulmonary A wave 
velocity is fi-equently increased. Additionally a valsalva manoeuvre will result in a 
reduction in E: A ratio if pseudonormalisation is present.
1.7.3.6 Aetiology.
A number of studies have shown that fibrosis rather than myocyte hypertrophy 
accounts for the development of diastolic dysfunction in hypertension. Matsubara et al 
(2000) demonstrated, using isolated papillary muscles fi*om hypertensive rats, that 
fibrosis rather than hypertrophy increased passive stiffiiess. This finding has been 
confirmed in two clinical studies. (Schwartzkopff 2000, Brilla 2000). Therefore it can 
be seen that measurement of diastolic function will therefore be a non-invasive 
measure of myocardial fibrosis.
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Other important causes besides sustained hypertension include hypertrophic 
cardiomyopathy, obesity, constrictive pericarditis and conditions that result in a 
restrictive cardiomyopathy for example amyloidosis, endomyocardial fibrosis and 
sarcoidosis.
1.7.3.7 Clinical Significance of Diastolic Dysfunction.
Impairment of diastolic fimction precedes systolic dysfimction in the progression of 
cardiac disease. Numerous studies have reported that between 30-40% of patients 
presenting with the clinical syndrome of cardiac failure have normal LV systolic 
function (Senni 1999). It is hypothesised that this apparent paradox is explained by 
the presence of diastolic dysfimction. Of more importance perhaps is that even in 
established left ventricular systolic dysfunction the degree of co-existent diastolic 
dysfunction determines the degree of cardiac limitation.
1.8 Exercise Induced Left ventricular Hypertrophy. (Athletes heart)
1.8.1 Historical perspective.
In 1884 Bergmann first observed that wild animals had larger hearts than similar 
domesticated animals. Henschen was the first to document exercise-induced changes 
in humans and in 1889 he described cardiac hypertrophy in cross-country skiers by 
percussing the cardiac contour (Henschen 1889). Henschen hypothesised that there 
was symmetrical hypertrophy and dilatation to compensate for the increase in venous 
return. This was based on the theory of normalising wall stress via the law of Laplace, 
which has been discussed earlier. The first post-mortem study was reported by Kirsh 
(1936) who examined the hearts of 35 athletes who died suddenly and reported the 
finding of hypertrophy. However this did not appear to be symmetrical. The
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pathological significance of this finding of hypertrophy has caused considerable 
debate throughout the later part of the last century and continues to do so.
1.8.2 Cardiovascular adaptation to exercise.
Adaptation occurs when regular physical activity is undertaken. The extent and the 
nature of the adaptation depend on the frequency, duration and nature of the exercise. 
There are two pure forms of exercise isotonic (dynamic) and isometric (static) 
however it should be accepted that almost aU sports require a mixture of both.
Isotonic exercise is thought to result in;
1 .Increased ventricular stroke volume.
2.Increased left ventricular end-diastolic volume.
3.Increased peak oxygen consumption. (V02 max)
4.1ncreased skeletal muscle respiratory enzyme concentrations and capillary muscle 
density.
5.Mass-to-volume ratio is unchanged.
Isometric exercise on the other hand is characterised by;
1.Increased left: ventricular mass.
2.No significant increase in V02 max.
3.No increase in LVEDD.
4.1ncreased mass-to-volume ratio.
Physiological ventricular dilatation and hypertrophy occur over a short period. Ehsani 
demonstrated that LVEDD increases within seven days and increases in left: 
ventricular wall thickness peaks at 3 to 5 weeks (Ehansi 1978). This requires an 
athlete to exercise for 30-60 minutes three to four times per week at 60-70% of his or 
her V02 max. The amount of hypertrophy present depends on the size, age, gender
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and numerous other influences. However, rather simplistically, larger, older athletes 
tend to get more significant hypertrophy.
These changes result in abnormalities in clinical examination, ECG and 
echocardiography.
1.8.3 Electrocardiographic changes.
Most ECG changes present in athletes are the result of high vagal tone and consist of;
1 .Sinus bradycardia is seen in most athletes.
2.33% may have sinus pauses greater than 2 seconds.
3.First, second and third degree block all occur more commonly in athletes. 
4.Incomplete right bundle branch block.
5.Vertical axis shift and voltage criteria for LVH.
6.ST-T wave change.
7.QT prolongation.
1.8.4 Echocardiographic changes.
Numerous echocardiographic studies have looked at exercise induced left ventricular 
hypertrophy. The largest being Pelliccia’s study o f947 elite Italian athletes (Pellicia
1991). The average ventricular septal waU thickness was 9.7mm (range extended 
from 6 to 16mm) with 98% of athletes having a septal wall thickness of less than 
12mm. It is noteworthy that only 16 athletes had a septal wall thickness of greater 
than 13mm which is the range in which hypertrophic cardiomyopathy may be 
suspected. The left ventricular internal diameter ranged from 40 to 66mm with a mean 
of 52m in comparison with a sedentary cohort who ranged from 40-52mm. The 
diastolic filling pattern was found to be within normal range.
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An overview of 28 studies performed by Maron (1986) demonstrated an average 
increase of 46% in left ventricular mass, 10% increase in LV cavity size and a 14% 
and 18% increase in LV posterior and anterior wall thickness respectively.
Therefore in summary the echocardiographic findings one may demonstrate in elite 
athletes are;
1. Increased posterior wall thickness (typically does not exceed 12mm)
2. Increased anterior septal thickness (typically does not exceed 15mm)
3. Increased LV cavity size.
4. Increased LV cavity mass (45%)
5. Increased right ventricular end-diastolic diameter.
6. Multivalvular regurgitation.
1.8.5 Pathological versus Physiological.
It remains a major point of discussion whether the changes described above are a 
physiological or pathological phenomenon. There are well described arguments on 
both sides which I will discuss.
The hypothesis that athlete’s heart is physiological is based on three main points. 
Firstly it has been well documented that exercise induced left ventricular hypertrophy 
regresses on cessation of exercise. Ehansi (1978) demonstrated a marked reduction in 
LVEDD and LV posterior wall thickness within 7 to 14 days of inactivity. A similar 
finding was demonstrated by Martin (1993) who reported a 20% reduction in LV 
mass after three weeks deconditioning. The authors suggest that the demonstration of 
regression on cessation of exercise confirms that exercise induced LVH is 
physiological.
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Secondly the only life expectancy study comparing athletes with sedentary controls 
reported a prolonged life expectancy within the athletes (Sama 1993).
Thirdly sudden death in athletes is exceptionally rare and is normally attributable to 
well described causes of sudden death
These arguments are countered quite simply however. Firstly the fact that athlete’s 
heart regresses on cessation of exercise should give us little comfort. Any form of 
LVH, for example secondary to hypertension or aortic stenosis regresses on removal 
of the pathological stimulus for example treatment of hypertension (Dahlof 1992) or 
valve replacement Kennedy 1977). Therefore it can be interpreted that exercise 
induced LVH is merely behaving in a fashion similar to established pathological 
LVH. Secondly the life expectancy study quoted is flawed with no effort made to 
exclude confounding variables such as smoking. Finally although sudden death is 
rare post mortem studies have revealed an incidence of “ idiopathic LVH” of 18% in 
this cohort (Maron 1980). Clearly no direct link can be drawn from this but this 
should raise concern.
1.8.6 Veteran Athletes.
Little evidence on veteran athletes is currently available. However the studies that are 
available suggest that the cardiovascular adaptation to high intensity exercise in this 
cohort may be different. A study performed by Nishimura (1980) compared a cohort 
of veteran athletes with younger subjects looking at echocardiographic variables. The 
findings reveal that the cohort of veteran athletes developed excessive hypertrophy, 
left atrial enlargement, ECG changes and also demonstrated some reduction in overall 
left ventricular fimction when compared to the younger cohort. A ftirther study by 
Miki (1994) which was a follow up study involving a cohort of veteran cyclists 
revealed incomplete regression of LVH on cessation of exercise and impaired
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diastolic function amongst the veteran cyclists. These features are not consistent with 
the overall hypothesis that exercise induced LVH is a physiological phenomena and it 
may well be that cardiovascular adaptation to prolonged high intensity exercise 
represents a different entity. A possible and plausible explanation for incomplete 
regression of LVH and impaired diastolic function would be the presence of 
interstitial fibrosis occurring as part of the hypertrophic process. Exercise induced 
LVH is traditionally thought to consist of myocyte hypertrophy alone. However we 
hypothesise that in veteran athletes the cardiovascular adaptation to prolonged high 
intensity exercise involves a degree of myocardial fibrosis in addition to the 
conventional myocyte hypertrophy. Myocardial fibrosis represents an important 
pathophysiological entity when present in others forms of LVH such as hypertensive 
heart disease and LVH secondary to aortic stenosis.
1.9 White Coat Hypertension.
White coat hypertension is a term used to describe patients who have persistently 
elevated office blood pressure but a normal ambulatory blood pressure. The incidence 
can vary markedly (12- 50%) depending on the definition used and the population 
studied (Verdecchia 1992,Pickering 1999). More recent work arising from the 
Pressione Arteriose Monitorate E Loro Associazioni (PAMELA) study describes a 
incidence of 7% in a random population and a minimum of 12% in untreated patients 
with stage I or II hypertension (Sega 2001). The pathological significance of “white 
coat hypertension” has been much debated and has been the subject of several trials. 
The studies have looked at the conventional markers of target organ damage in 
sustained hypertension. The results vary significantly which can at least be partly
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explained by the varying definitions for “ white coat hypertension”. Too high a 
daytime reading will include patients with genuine sustained hypertension and thus 
demonstrate evidence of end-organ damage whilst too low a cut-off will contain a 
large proportion of normotensive patients thus leading to negative results. This 
dilemma illustrates a major persisting problem with the definition of hypertension. 
Namely providing an arbitrary cut-off in a continuous variable.
Several authors have demonstrated increased LV mass amongst the study 
population (Kuwajima 1993, Cerasola G 1995, MuschoU 1998, Palatini 1998) whilst 
authors have failed to demonstrate a significant difference (White WB 1989, Gosse P 
1993, Verdecchia 1995). Studies of diastolic filling have shown a similar dispersion 
of positive and negative results. Palatini et al (1998) demonstrated normal diastolic 
filling whilst Cerasola et al (1995) and Glen at al (1996) revealed a significant 
impairment in diastolic filling.
Therefore in the presence of conflicting data on the outcome of “white coat 
hypertension”, experts remain divided on its pathological significance.
A major omission in the current literature regarding white coat hypertension is 
the absence of any assessment of the collagen equilibrium. Fibrosis occurs at an early 
stage in the development of hypertension and therefore assessment of fibrosis would 
provide important additional information on the presence or absence of target organ 
damage in white coat hypertension and may also provide information about the blood 
pressure levels at which changes to the extracellular matrix occur. Perhaps giving 
further information about what can be truly regarded as a normal blood pressure.
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Hypothesis.
1 .Both collagen synthesis and degradation are abnormal in untreated essential 
hypertension.
2.Collagen markers will provide a non-invasive measurement of fibrosis in 
hypertensive heart disease and a means of monitoring this process.
3.Exercise induced LVH in veteran athletes is associated with abnormalities in the 
collagen equilibrium and fibrosis.
4.Target organ damage in the form of fibrosis occurs in white coat hypertension. 
Alterations to the collagen equilibrium occur at blood pressure levels previously 
thought to be normal.
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Chapter!
Experimental Methods and Results of
Normal Volunteers.
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2.1 Investigation of collagen turnover in untreated essential hypertension.
2.1.1 Ethical Approval
Ethical approval was obtained from the local ethics committee. All subjects received a 
full written and verbal explanation of the investigations involved and the aims of the 
study. Written consent was obtained in all cases prior to any investigations being 
performed.
2.1.2 Recruitment.
Patients were recruited via two main sources. Firstly from the Hypertension clinic run 
by Dr FG Dunn in StobhiU General Hospital. This clinic is run on a weekly basis and 
there are on average four new referrals per week. Secondly, direct referrals from local 
General Practitioners were received. The General Practitioners were made aware of 
the research project by mail. The project was set up in a manner that offered the GPs a 
service for assessing patients with suspected hypertension and thus maximised 
referrals. Subjects were enrolled from August 1997 until July 1999.
2.1.3 Inclusion criteria.
Subjects were aged 18 years or over and had never treated essential hypertension.
This was defined as three supine blood pressure readings with a mercury 
syphgmanometer greater than 140/90mmHG and a mean 24hour blood pressure of 
greater than 140/90mmHG.
2.1.4 Exclusion criteria.
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Exclusion criteria were based on two main premise. Firstly the exclusion of 
subjects with conditions, which would result in, left ventricular hypertrophy. Namely 
the presence of flow limiting aortic stenosis (defined as an aortic gradient calculated 
by the modified BerouUi equation of greater than 20mmHG), Secondly as our 
biochemical assays used in this study are not specific for myocardial fibrosis carefiil 
screening of the patients to exclude conditions which could result in fibrosis was 
undertaken. Therefore exclusion criteria were conditions that were known to result in 
myocardial or tissue fibrosis. These comprised renal impairment (serum creatinine 
>130pmol/l), coronary artery disease (defined as symptomatic angina, history of 
previous myocardial infarction or the presence of ECG evidence of ischaemia or 
previous myocardial infarction), secondary hypertension, malignancy of any site, 
pulmonary fibrosis, connective tissue disorders, significant hepatic dysfunction 
(defined as any hepatic enzyme double the upper limit of normal on routine 
biochemical analysis), left ventricular systolic dysfunction (defined as 
echocardiographic calculated ejection fraction of <35% or “eyeball” assessment of 
impaired left ventricular fimction),COPD (defined as regular use of inhalers, clinical 
or radiological hyperinflation or greater than 2 respiratory tract infections per year), 
asthma( defined as the presence of clinical bronchospasm, history of bronchospasm or 
the use of inhalers) and recent surgery. These conditions were identified by careful 
history taking, frill clinical examination, urinalysis. Chest X-ray, if required, ECG, 
Exercise stress testing if appropriate and echocardiography.
2.1.5 Normal Volunteers.
Normal volunteers were recruited via a local advertising campaign. All subjects were 
normotensive as defined by three supine blood pressure recordings at rest of less than 
140/90mmHG and exclusion criteria as above applied.
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2.1.6 Study Conditions.
Clinical investigations were performed on one day at a standard time. Blood pressure 
measurement was taken in a quiet room after 15 minutes rest. Biochemical assays 
were taken immediately following this with venesection of 20ml of venous blood. A 
full cardiovascular history and systemic enquiry was taken. A full clinical 
examination of the cardiovascular, respiratory and abdominal systems was performed. 
A random urine sample was obtained and urinalysis performed.
2.1.7 Baseline Investigations.
Haematology: haemoglobin, haematocrit and mean cell volume.
Biochemistry: sodium, potassium, chloride, bicarbonate, urea, creatinine, corrected 
calcium, albumin. Alkaline Phosphatase, Bilirubin, Gamma GT, 
Alanaine aminotransferase, Aspartate aminotranseferase.
2.1.8 Electrocardiogram (ECG).
This was performed with the subjects in a supine resting state using a standard 
Pagewriter ECG machine with a paper speed of 25mm/sec. Standard skin preparation 
and lead positions were used. The standard 12 leads were recorded simultaneously. 
All ECGs were analysed by a single observer (MM Lindsay). The criteria used to 
diagnose left atrial abnormalities were;
1. Terminal forces m VI equal to or more negative than -0.04mm sec, as obtained 
from the product of the depth of the terminal negative deflection and its duration.
2. Bipeak interval in deeply notched P wave wider than 0.04sec in any lead.
3. P wave in lead II higher than 0.3mV or wider than 0.12sec.
These criteria were adapted from those reported and validated by Tarazi (1966). 
Subjects were classified as having left atrial abnormalities if they had one or more of 
the above criteria on ECG. The presence of LVH and ST-T abnormalities was
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defined using the Glasgow Blood Pressure Clinic criteria. (Dunn, 1990) LVH being 
defined as SVl + RV5>35mm or deepest precordial S and Tallest R>40mm. LVH 
with ST-T changes being defined as (a) LVH as above with ST-T depression > 1mm 
and/or T wave inversion >lmm in leads V5 and V6, or (b) LVH as above with ST 
depression and/or T wave inversion >lmm in any other lead except III, aVr, avl (if p 
wave inverted) or VI. Finally ST-T changes only was defined as ST-T changes 
>lmm as above in the absence of LVH.
2.1.9 Echocardiography,
Patients were studied using a Vingmed CFM800 sonos and a Vingmed System 5 echo 
machine. Examinations were made in a darkened room in the standard left lateral 
position. Images were stored on videotape and digital archiving facility (Echopac). A 
standard two dimensional echocardiographic study was performed. Obtaining the 
standard views: long axis parasternal, short axis parasternal and apical two, four and 
five chamber views.
M-Mode measurements were taken in the parasternal long axis view the cursor across 
the tips of the mitral valve leaflets. Measurements were taken of the left ventricular 
septum, posterior wall and internal dimensions at the end of diastole using the leading 
edge technique according to the guidelines laid down by the American Society of 
Echocardiography. (Sahn 1978) Systolic measurements were taken again using the 
leading edge technique. An average of at least three measurements was taken. Left 
ventricular mass was calculated using the formula validated by Reichek and Devereux 
(1977).
Left Ventricular mass=1.04(IVS+LVID+PWT)^-(LVID)’)-14g
IVS= Interventricular septum
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LVID= Left ventricular internal diameter in diastole 
PWT= Posterior wall thickness in diastole.
The figure obtained was then divided by the body surface area to give a value for Left 
Ventricular Mass Index.
Left ventricular systolic fimction was assessed by M-mode calculation of fractional 
shortening and “eyeball” assessment. Fractional shortening was derived from the 
following equation.
Fractional Shortening = (LVID-LVIDs)LVID 
LVID= Left ventricular internal dimension in diastole 
LVIDs= Left ventricular internal dimension in systole.
Pulsed wave Doppler was used to assess diastolic filling. To obtain optimal velocity 
measurements the angle between the ultrasonic beam and the mitral inflow was kept 
to a minimum and in all cases was less than 20%. Measurement of E: A ratio and the 
E wave deceleration (E dec) time were made in the apical four chamber view with a 
cursor at the mitral valve inflow using pulsed wave doppler. E:A ratio was measured 
as the ratio of the peak velocity of the E wave to the peak velocity of the a wave. E 
wave deceleration time was measured as the time elapsed from the peak of the E wave 
to the baseline. An average of three measurements was taken at end expiration. 
Isovolumic relaxation time (IVRT) was measured with the cursor between the mitral 
inflow and the left ventricular outflow tract in the apical five chamber using pulsed 
wave Doppler. Measurement was taken from the completion of the aortic forward 
flow until the onset of the E wave. An average of three measurements in end 
expiration was taken. A single observer (M Lindsay) made all measurements. Using 
digital archiving images intra-observer variability was tested in a blinded fashion.
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Intra- observer variability was 3.5%, 4%, 10% and 9% for E: A ratio, E deceleration 
time, IVRT and calculated left ventricular mass index (LVMI) respectively.
2.1.10 Blood Pressure Measurement.
The blood pressure was measured using a standard mercury syphgmanometer. Cuff 
size was chosen such that the bladder was at least 80% of the circumference of the 
arm. The bladder was placed over the brachial artery and the cuff inflated. Systolic 
pressure was measured as when the first sounds were heard and the diastolic pressure 
when the sounds disappeared completely (Phase V). Measurements were taken to the 
nearest 2mmHG. The pressure in both arms was taken and the highest pressure 
recorded.
2.1.11 24Hour Blood pressure measurement.
An oscillometric spacelab monitor was used. The bladder of the cuff was situated over 
the brachial artery. Five measurements were performed prior to allowing the subject 
home to ensure BP monitor was functioning normally and the subject would to 
tolerate the monitor. Readings were made every 30 minutes through the daytime 
period and every hour over the nocturnal period. Patients must have at least 1 reading 
per hour, 80% of total readings successful and at least a total of 30 readings over the 
24-hr period for the blood pressure reading to be accepted. AU readings taken during 
this period were documented and mean daytime; mean nocturnal and mean 24 hr 
blood pressures were calculated. AU taped were analysed by one observer (M 
Lindsay).
2.1.12 Biochem ical Measurement.
Routine biochemical measurements were taken and analysed in the standard fashion. 
AU samples were taken at a standard time after thirty minutes in the supine position. 
Samples were immediately centrifuged and the plasma layer removed. The separated
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plasma was divided into three equal aliquots and frozen at minus 80*^ 0. Samples were 
not thawed and refrozen. All samples were run in duplicate.
We used a commercially available TIMP-1 assay obtained from Amersham. 
This is a modification of the method developed by Plumpton (1995). Standards and 
diluted plasma were incubated in a microtitre well which is coated with anti-TIMP 
antibody. After incubation and washing the bound TIMP-1 is measured by reaction 
with a second peroxidase labelled antibody and the oxidised substrate read in a 
spectrometer at 450 nm. We have shown linearity to lOOng/ml, all samples were 
analysed in duplicate and intra-assay variability was 4.5%.
Plasma CITP was measured by radioimmunoassay using a polyclonal antibody 
direct against CITP. (Ristelli, 1993) All samples were run in duplicate with the 
intrassay variability calculated as 4.3%.
Plasma PICP was measured using a radioimmunoassay. Samples were run in 
duplicate with the calculated intrassay variability of 4.2%.
Renin and aldosterone were measured using a radioimmunoassay through a 
routine analyser.
2.2 Studies of biochemical evidence of fibrosis in Veteran Athletes.
2.2.1 Ethical Approval
Ethical approval was obtained from the local ethics committee. All subjects received a 
full written and verbal explanation of the investigations involved and the aims of the 
study. Written consent was obtained in all cases prior to any investigations being 
performed.
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2.2.2 Inclusion Criteria.
We recruited a cohort of participating athletes by contacting the Scottish Veteran 
Harriers Association. A list of members was obtained from the chairman and 
individual members were contacted by mail with details and aims of the study 
provided. We aimed to enrol a population of veteran endurance athletes training on a 
weekly basis and participating in elite veteran events to ensure the presence of 
exercise induced cardiovascular alterations in a proportion of these subjects. Inclusion 
criteria therefore consisted of 1. Age>45 years 2. Subjects had to have been 
competing for more than 10 years at a competitive level 3. High intensity training 
defined as running more than 30 miles per week 4. Regularly competing in elite 
veteran endurance events.
2.2.3 Exclusion Criteria.
Exclusion criteria were based on two main premise. Firstly the exclusion of subjects 
with conditions which would result in left ventricular hypertrophy. Namely 
hypertension (defined as three supine readings greater than 140/90mmHG) and the 
presence of flow limiting aortic stenosis (defined as an aortic gradient calculated by 
the modified BerouUi equation of greater than 20mmHG). Secondly as our 
biochemical markers of fibrosis were not specific for myocardial fibrosis then 
subjects with any condition which would result in fibrosis and thus give confounding 
results were excluded. These comprised renal impairment (serum creatinine 
>130pmoFl), coronary artery disease (defined as symptomatic angina, history of 
previous myocardial infarction or the presence of ECG evidence of ischaemia or 
previous myocardial infarction), secondary hypertension, malignancy of any site, 
pulmonary fibrosis, connective tissue disorders, significant hepatic dysfunction 
(defined as any hepatic enzyme double the upper limit of normal on routine
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biochemical analysis), left ventricular systolic dysfunction (defined as 
echocardiographic calculated ejection fraction of <35% or “eyeball” assessment of 
impaired left ventricular fimction),COPD (defined as regular use of inhalers, clinical 
or radiological hyperinflation or greater than 2 respiratory tract infections per year), 
asthma( defined as the presence of clinical bronchospasm, history of bronchospasm or 
the use of inhalers) and recent surgery. These conditions were identified by careful 
history taking, full clinical examination, urinalysis. Chest X-ray, if required, ECG, 
Exercise stress testing if appropriate and echocardiography.
2.2.4 Normal volunteers.
Normal volunteers were recruited via a local advertising campaign in the local press. 
Exclusion criteria as defined above applied. In addition normal subject were sedentary 
defined as participating in less than one hour of regular physical exertion per week.
2.2.5 Baseline Investigations.
Haematology: haemoglobin, haematocrit and mean cell volume.
Biochemistry: sodium, potassium, chloride, bicarbonate, urea, creatinine, corrected 
calcium, albumin. Alkaline Phosphatase, Bilirubin, Gamma GT, 
Alanaine aminotransferase. Aspartate aminotranseferase.
2.2.6Blood Pressure Measurement.
The blood pressure was measured using a standard mercury syphgmanometer. Cuff 
size was chosen such that the bladder was at least 80% of the circumference of the 
arm. The baldder was placed over the radial artery and the cuff inflated. Systolic 
pressure was measured as when the first sounds were heard and the diastolic pressure 
when the sounds disappeared completely (Phase V). Measurements were taken to the 
nearest 2mmHG. The pressure in both arms was taken and the highest pressure 
recorded.
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2.2. lElectrocardiograhy.
This was performed with the subjects in a supine resting state using a standard 
Pagewriter ECG machine with a paper speed of 25mm/sec. Standard skin preparation 
and lead positions were used. The standard 12 leads were recorded simultaneously.
All ECGs were analysed by a single observer (MM Lindsay). The criteria used to 
define the presence of LVH, ST-T abnormalities and atrial abnormalities were 
identical to those described above
2.2.8 Echocardiograhic study.
Patients were studied using a Vingmed CFM800 sonos and a Vingmed System 5 echo 
machine. Examinations were made in a darkened room in the standard left lateral 
position. Images were stored on video tape and digital archiving facility (Echopac). A 
standard two dimensional echocardiographic study was performed. Obtaining the 
standard views: long axis parasternal, short axis parasternal and apical two, four and 
five chamber views. M Mode and Doppler measurements were taken in a 
standardised fashion as described above. Measurement of LV dimensions in diastole 
and systole were taken and calculation of LVMI made according to the method 
described by Reichek and Devereux. (1977). The formula is described above. Doppler 
measurement of E: A ratio as an estimate of diastolic filling was performed by the 
method again described above.
2.2.9 Biochemical assessment of Collagen metabolism.
Routine biochemical measurements were taken and analysed in the standard fashion. 
All samples were taken at a standard time after thirty minutes in the supine position. 
Samples were immediately centrifuged and the plasma layer removed. The separated
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plasma was divided into three equal aliquots and frozen at minus 80^C. Samples were 
not thawed and refrozen. All samples were run in duplicate.
We used a commercially available TIMP-1 assay obtained from Amersham. 
This is a modification of the method developed by Plumpton (1995). All samples 
were analysed in duplicate and intra-assay variability was 4.5%.
Plasma ITCP was measured by radioimmunoassay using a polyclonal antibody 
direct against ITCP. (Risteli 1993) All samples were run in duplicate with the 
intrassay variability calculated as 4.3%.
Plasma PICP was measured using a radioimmunoassay. Samples were run in 
duplicate with the calculated intrassay variability of 4.2%.
2.3 Studies of biochemical evidence of fibrosis in “White Coat” and mild 
Hypertension.
2.3.1 Ethical Approval
Ethical approval was obtained from the local ethics committee. All subjects received a 
full written and verbal explanation of the investigations involved and the aims of the 
study. Written consent was obtained in all cases prior to any investigations being 
performed.
2.3.2 Recruitment.
Subjects were recruited from our Hypertension clinic and direct referral from local 
General Practitioners as described above.
2.3.3 Normal Volunteers.
Normal subjects were recruited via a local advertising campaign as described above.
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2.3.4 Inclusion Criteria.
Subjects were aged 18 or over. And had been provisionally diagnosed but never 
treated as hypertensive by their general Practitioner. Subjects had three supine blood 
pressure readings greater than 140/90mmhg. However had mean 24 hour ambulatory 
blood pressure readings of less than 140/90mmhg. Blood pressure is normally 
distributed variable and definitions of normal and abnormal therefore have to be made 
in an arbitrary fashion. Therefore the definition of what is a truly normal 24hour 
ambulatory blood pressure recording is variable. Therefore this cohort was then 
subdivided and analysed in three separate cohorts 1. Subjects with mean daytime 
systolic blood pressure of greater than 140mmhg. 2. Subjects with mean daytime 
systolic blood pressure of 135-140mmHg. 3. Mean daytime blood pressure of less 
than 135/85mmhg. This cutoff meets with the definition provided by the British 
Hypertension Society.
2.3.5 Exclusion criteria.
The biochemical assays used in this study are not specific for myocardial 
fibrosis. Therefore careful screening of the patients to exclude conditions which could 
result in fibrosis was undertaken. Therefore exclusion criteria were conditions that 
were known to result in myocardial or tissue fibrosis. These comprised renal 
impairment (serum creatinine >130pmol/l), coronary artery disease (defined as 
symptomatic angina, history of previous myocardial infarction or the presence of 
ECG evidence of ischaemia or previous myocardial infarction), secondary 
hypertension, malignancy of any site, pulmonary fibrosis, connective tissue disorders, 
significant hepatic dysfunction (defined as any hepatic enzyme double the upper limit 
of normal on routine biochemical analysis), left ventricular systolic dysfunction 
(defined as echocardiographic calculated ejection fraction of <35% or “eyeball”
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assessment of impaired left ventricular function),COPD (defined as regular use of 
inhalers, clinical or radiological hyperinflation or greater than 2 respiratory tract 
infections per year), asthma( defined as the presence of clinical broncho spasm, history 
of bronchospasm or the use of inhalers) and recent surgery. These conditions were 
identified by careful history taking, full clinical examination, urinalysis, Chest X-ray, 
if required, ECG, Exercise stress testing if appropriate and echocardiography.
2.3.6 Study Conditions.
Clinical investigations were performed on one day at a standard time. Blood pressure 
measurement was taken in a quiet room after 15 minutes rest. Biochemical assays 
were taken immediately following this with venesection of 20ml of venous blood. A 
full cardiovascular history and systemic enquiry was taken. A full clinical 
examination of the cardiovascular, respiratory and abdominal systems was performed. 
A random urine sample was obtained and urinalysis performed.
2.3.7 Baseline Investigations.
Haematology: haemoglobin, haematocrit and mean cell volume.
Biochemistry: sodium, potassium, chloride, bicarbonate, urea, creatinine, corrected 
calicum, albumin. Alkaline Phosphatase, Bilirubin, Gamma GT, 
Alanaine aminotransferase, Aspartate aminotranseferase.
2.3.8 Electrocardiography.
This was performed with the subjects in a supine resting state using a standard 
Pagewriter ECG machine with a paper speed of 25mm/sec. Standard skin preparation 
and lead positions were used. The standard 12 leads were recorded simultaneously. 
All ECGs were analysed by a single observer (MM Lindsay). The criteria used to 
define the presence of LVH, ST-T abnormalities and atrial abnormalities were 
identical to those described above
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2.3.9 Blood Pressure Measurement
The blood pressure was measured using a standard mercury syphgmanometer. Cuff 
size was chosen such that the bladder was at least 80% of the circumference of the 
arm. The baldder was placed over the radial artery and the cuff inflated. Systolic 
pressure was measured as when the first sounds were heard and the diastolic pressure 
when the sounds disappeared completely (Phase V). Measurements were taken to the 
nearest 2mmHG. The pressure in both arms was taken and the highest pressure 
recorded.
2.3.10 24Hour Blood pressure measurement.
An oscillometric spacelab monitor was used. The bladder of the cuff was situated over 
the brachial artery. Five measurements were performed prior to allowing the subject 
home to ensure BP monitor was functioning normally and the subject would to 
tolerate the monitor. Readings were made every 30 minutes through the daytime 
period and every hour over the nocturnal period. Patients must have at least 1 reading 
per hour, 80% of total readings successfiil and at least a total of 30 readings over the 
24-hr period for the blood pressure reading to be accepted. All readings taken during 
this period were documented and mean daytime; mean nocturnal and mean 24 hr 
blood pressures were calculated. All taped were analysed by one observer (M 
Lindsay).
2.3.11 Echocardiograhic study.
Patients were studied using a Vingmed CFM800 sonos and a Vingmed System 5 echo 
machine. Examinations were made in a darkened room in the standard left lateral 
position. Images were stored on video tape and digital archiving facility (Echopac). A 
standard two dimensional echocardiographic study was performed. Obtaining the 
standard views: long axis parasternal, short axis parasternal and apical two, four and
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five chamber views. M Mode and Doppler measurements were taken in a 
standardised fashion as described above. Measurement of LV dimensions in diastole 
and systole were taken and calculation of LVM made according to the method 
described by Reichek and Devereux. (1977) Measurement of LVM was then indexed 
for body surface area to provide LVMI. The formula is described above. Doppler 
measurements of E: A ratio, E wave deceleration time and Isovolumic relaxation time 
(IVRT) as estimates of diastolic filling were performed by the method again described 
above.
2.3.12 Biochemical Measurement.
Routine biochemical measurements were taken and analysed in the standard fashion. 
All samples were taken at a standard time after thirty minutes in the supine position. 
Samples were immediately centrifuged and the plasma layer removed. The separated 
plasma was divided into three equal aliquots and firozen at minus SO'^ C. Samples were 
not thawed and refi'ozen. All samples were run in duplicate.
We used a commercially available TIMP-1 assay obtained fi*om Amersham. 
This is a modification of the method developed by Plumpton (1995). All samples 
were analysed in duplicate and intra-assay variability was 4.5%.
Plasma ITCP was measured by radioimmunoassay using a polyclonal antibody 
direct against ITCP. (Risteli, 1993) All samples were run in duplicate with the 
intrassay variability calculated as 4,3%.
Plasma PICP was measured using a radioimmunoassay. Samples were run in 
duplicate with the calculated intrassay variability of 4.2%.
Renin and aldosterone were measured using a radioimmunoassay through a 
routine analyser.
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2.4 Studies in Normal Volunteers.
As described above normal volunteers were recruited from a local advertising 
campaign and from friends and colleagues within the Cardiology department at 
Stobhill Hospital. 50 normal subjects were enrolled.
Exclusion criteria consisted of hypertension, aortic stenosis, regular aerobic exercise 
and conditions that may result in tissue fibrosis. A detailed list of these conditions is 
detailed in previous section.
All normal volunteers underwent detailed history and physical examination to exclude 
the aforementioned conditions.
2.4.1 Ethical Approval and consent.
Ethical approval was obtained from the local ethics committee. Verbal and written 
consent was obtained in all cases.
2.4.2 Study Conditions.
Clinical investigations were performed on one day at a standard time. Blood pressure 
measurement was taken in a quiet room after 15 minutes rest. Biochemical assays 
were taken immediately following this with venesection of 20ml of venous blood. A 
full cardiovascular history and systemic enquiry was taken. A full clinical 
examination of the cardiovascular, respiratory and abdominal systems was performed. 
A random urine sample was obtained and urinalysis performed.
2.4.3 Baseline Investigations.
Haematology: haemoglobin, haematocrit and mean cell volume.
Biochemistry: sodium, potassium, chloride, bicarbonate, urea, creatinine, corrected 
calcium, albumin. Alkaline Phosphatase, Bilirubin, Gamma GT, 
Alanaine aminotransferase. Aspartate aminotranseferase.
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lAABlood Pressure Measurement
An average of three supine blood pressure recordings were taken using a mercury 
sphygmomanometer in a standardised fashion detailed above.
2A.5Electrocardiogram.
Standard 12 lead electrocardiograms were obtained. Each was analysed for the 
presence of voltage criteria for LVH, the presence of ST-T changes and atrial 
abnormalities using predefined criteria described above.
2.4. 6Echocardiography.
Each subject underwent echocardiographic study using a standardised protocol 
described above.
2.4.7 Biochemical Measurement
Routine biochemical measurements were taken and analysed in a standard fashion. 
Samples were prepared as described above and measurement of TIMP-1, CITP and 
PICP were made using the assays and techniques described above.
All physical examinations. Blood pressure measurement, ECG analysis and 
Echocardiograms were performed by a single operator. ( M Lindsay).
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The results of these investigations on normal volunteers are presented below.
2.4.8 Results for Normal Volunteers.
Table 2.1 : Baseline characteristics+SEM
Parameter Normal Volunteers
Number 50
Sex (male/female) 23/27
Age (years) 52.1+1.5
Smoker (yes/no/ex) 35/7/8
Systolic Blood Pressure (mmHg) 129±2.6
Diastolic Blood Pressure (mmHg) 77+2
Urea 5.1+0.3
Creatinine 97+2.5
Gamma GT 30±5.6
Table 2.2: Electrocardiograhic data.
Parameter Number
LVH 0
ST-T change 0
Atrial Abnormalities. 4
80
Table 2.3: Echocardiographic data. ( mean ±SEM)
Parameter Normal volunteers.
Interventricular Septal thickness in 
diastole (cm)
0.9+0.03
Left Ventricular Internal Diameter in 
diastole(cm)
4.8+0.07
Left ventricular posterior wall thickness 
in diastole (cm)
0.91±0.02
Relative wall thickness 0.37+0.01
Left ventricular Mass Index (g/m^) 97+3
Maximal E wave Velocity (cm/s) 0.73+0.03
Maximal A wave velocity (cm/s) 0.70+0.03
E:A ratio 1.15+0.03
Isovolumic Relaxation Time (ms) 100+0.03
E wave decleration time(ms) 19.3+0.9
Aortic velocity (m/s) 1.07+0.04
Fractional Shortening (%) 40+1.6
Left Ventricular ejection fraction (%) 77+2
Left Atrial Diameter in systole (cm) 3.3+0.8
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Table 2.4 Biochemical markers of Collagen metabolism.
Parameter Mean Standard Error 
of Mean
Standard
Deviation.
Range.
TIMP-l(rig/l) 253 11 76 99-421
CITP(|Lig/l) 2.9 0.15 0.8 1.8-5.1
PlCP(iag/l) 166 9 48 85-262
Table 2.5 Markers of the Renin Angiotensin system. (meartfcSEM)
Parmeter Normal volunteers.
Aldosterone (r)g/100ml) 9.3+1
Renin 15+2
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Chapter 3:
Validation and Standardisation of 
biochemical assays and 
echocardiographic measurement.
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Validation o f  Biochemical Assays.
3.1 Introduction.
As discussed in the introduction, biochemical assessment of the collagen equilibrium 
has increasingly been used for non-invasive monitoring of end-organ fibrosis. This 
has been demonstrated in numerous conditions. For example, pulmonary fibrosis 
(Montano, 1989), hepatic fibrosis (Li, 1994), bone metabolism and renal disease.
The measurement of these markers forms a major part of this thesis and 
therefore requires careful validation. To achieve this we performed intra-assay 
variability on three assays used. This was not a longitudinal study therefore inter­
assay variability was not performed for the purposes of this thesis. However, inter­
assay and batch variability has been separately assessed within our laboratory with 
satisfactory results, 4.9% for TIMP-1, 6.9% forPlCP and 6.4% for CITP. Every effort 
was made to standardise sample collection and measurement. The venous blood 
samples were taken in standard conditions and at a standard time of day to exclude 
any effect diurnal variation may have on measurement. The samples were 
immediately centrifuged at 3000rpm for seven minutes and the plasma layer was 
removed. This was then divided into equal aliquots and stored at -80oC. The samples 
were not thawed and refi'ozen on any occasion. Several preliminary analyses of 
normal samples were performed prior to analysis of the study subjects to ensure 
adequate reproducibility for each of the assays. All samples were analysed in 
duplicate.
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The assays were purchased as commercially available kits. Every effort was 
made to mamtaiu quality control of the assay. Inter-assay and batch variability was 
tested as described above with limited variability.
3.2 Methods
3.2.1 Assay variability
To adequately assess assay variability we chose samples from our cohort of normal 
volunteers, hypertensive subjects, white coat hypertensives and athletes. This allowed 
assessment of variability across the ftiU range of absolute values for each of the three 
biochemical assays used. Our laboratory technician who had no prior knowledge of 
the source of the samples randomly selected samples to be analysed. Intra-assay 
variability was tested by running the samples in duplicate (which was our normal 
practice throughout the study).
3.3 Results
3.3.1 Assay variability.
The results for each of the three assays are expressed in the form of absolute and 
percentage difference. The raw data is presented in tabular format and the results are 
also presented in graphical format as a Pearson’s correlation and in a Bland-Altman 
graph.
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3.3.2 TIMP-1
Forty samples were analysed for intra-assay variability of TIMP-1. These are 
presented in tabular format (Table 3.1). The absolute values of the samples studied 
ranged from 107nanograms/ml to 764 nanograms/ml and therefore was a 
representative selection. The intra-assay variability of TIMP-1 was 4.6% (95% Cl 3.9- 
5.2). The correlation co-efiQcient was 0.998. There was no variation in variability 
across the range of absolute values.
Table 3.1: Intra-assay variability for Plasma TIMP-1. Absolute and percentage 
differences are shown.
TIMP Sample 1 TEMP Sample 2 Absolute Difference % difference.
(nanograms/ml) (nanograms/ml)
205 213 8 3.8
118 125 7 5.8
146 152 6 4
108 115 7 6.2
241 256 15 6
121 126 5 4
162 168 6 3.6
117 129 12 9.8
110 118 8 7
152 158 6 3.9
111 117 6 5.3
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135 146 11 7.8
102 104 2 1.9
248 257 9 3.6
146 153 7 4.7
102 103 1 0.9
286 296 10 3.4
121 126 5 4
356 364 8 2.2
764 774 10 1.3
243 250 7 2.9
114 122 8 6.8
186 194 8 4.2
110 110 0 0
165 170 5 3
250 263 13 5.1
147 158 11 7.2
133 139 6 4.4
107 111 4 3.7
153 165 12 7.5
191 203 12 6.1
128 136 8 6.1
107 109 2 1.9
194 202 8 4
136 145 9 6,4
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123 131 8 6.3
141 146 5 3.5
356 367 11 3
308 323 15 4.7
113 121 8 6.8
Figure 3.1: Bland Altman graph illustrating intra-assay variability of plasma TIMP-1.
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Figure 3.2: Scatterplot graph illustrating intra-assay variability of plasma TIMP-1.
900
800 y ■ 1 0077* + 5 .6 2B3 
F? = 0.9987 ^
700
600
500
* -  400
300
200
100
300 400 500 600 700 800 9000 100 200
TIMP-1
90
3.3.3 CITP
Forty samples were analysed to assess intra-assay variability of the CITP assay. The 
range studied was 2.4pg/l to 8.9pg/l and therefore again was a representative sample 
of all our study populations. The raw data is presented in tabular format below in 
Table 3.2. The intra-assay variability of CITP was 4.4% (95% Cl 3.2-5.6). The 
correlation co-efiScient was 0.95. There was no variation in variability across the 
range of absolute values.
Table 3.2. Intra-assay variability for plasma CITP comparing samples 1 and 2. 
Absolute and percentage differences are shown.
CITP Assay 1 CITP Assay 2 Absolute
Difference
% Difference.
3.4271 3.4164 0.0107 0.312701
4.9664 4.9993 0.0329 0.660285
3.8824 3.8403 0.0421 1.090306
3.962 4.557 0.595 13.98158
4.1611 3.9908 0.1703 4.178526
4.2453 3.8279 0.4174 10.34525
2.4355 2.416 0.0195 0.802932
3.2678 3.5521 0.2843 8.3392
3.414 3.5654 0.1514 4.33873
3.4967 3-1794 0.3173 9.508256
4.4027 4.391 0.0117 0.266103
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4.2979 4.3069 0.009 0.209186
3.5147 3.5027 0.012 0.342007
3.5267 3.269 0.2577 7.585435
4.6563 4.5176 0.1387 3.023961
5.2914 5.0254 0.266 5.157438
4.8089 4.9555 0.1466 3.002868
4.6616 4.9132 0.2516 5.256231
3.5533 3.6819 0.1286 3.55504
3.3782 2.9888 0.3894 12.23643
4.4261 4.643 0.2169 4.900477
3.8601 4.2146 0.3545 8.783449
3.9421 3.87 0.0721 1.845878
3.9109 3.8973 0.0136 0.348352
3.2218 3.0564 0.1654 5.269362
3.9271 3.71 0.2171 5.686074
4.7109 4.6191 0.0918 1.967888
6.8633 6.1342 0.7291 11.23196
8.8998 8.8766 0.0232 0.26102
6.4913 5.9706 0.5207 8.361703
7.6106 7.3361 0.2745 3.673617
4.5768 4.557 0.0198 0.433554
5.8742 5.7921 0.0821 1.407485
6.0513 5.5559 0.4954 8.540938
4.6178 4.7056 0.0878 1.883473
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4.7056 4.7189 0.0133 0.28224
4.2979 4.3069 0.009 0.209186
4.3936 4.4027 0.0091 0.206908
5.9419 6.3987 0.4568 7.406687
6.3844 5.8413 0.5431 8.890453
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Figure 3.3: Bland Altman graph illustrating intra-assay variability in Plasma CITP.
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Figure 3.4: Scatterplot graph illustrating intra-assay variability in Plasma CITP.
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3.3.4 PICP
Forty samples were analysed to assess intra-assay variability of the plasma PICP 
assay. The range of absolute values studied was 82pg/l to 216pg/l and therefore again 
was a representative sample. The raw data is presented below in tabular format in 
Table 3.3. The intra-assay variability of the PICP assay was 4.2% (95% Cl 3.3-5.3%). 
The correlation co-efficient was 0.93. There was no variation in variability across the 
range of absolute values.
Table 3.3: Intra-assay variability for plasma PICP comparing sample 1 and 2. 
Absolute and percentage differences are shown.
PICP assay 1 PICP assay 2 Absolute
Difference
% Difference.
113.32 118.18 4.86 4.112371
111.67 102.76 8.91 7.978866
143.49 147.61 4.12 2.832199
144.69 144.04 0.65 0.449267
158.96 155.58 3.38 2.126321
199.86 190.73 9.12 4.563423
124.2 130.89 6.69 5.247882
106.15 105.31 0.74 0.794476
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108.43 99.723 8.707 8.376142
160.17 147.73 12.44 8.091057
190.18 199.78 9.6 4.926361
216.63 206.29 10.34 4.892359
131.02 126.29 4.73 3.6775
151.49 132.98 18.51 12.21863
149.65 139.04 10.65 7.386088
132.95 127.23 5.72 4.398647
107.51 109.6 2.09 1.92538
118.16 117.26 0.9 0.764591
151.53 149.25 2.28 1.516159
148.64 163.11 14.47 9.299486
158.2 138.39 19.81 13.40597
160.72 155.07 5.65 3.579347
148.92 149.29 0.37 0.248456
134.78 131.08 3.7 2.783839
130.23 143.69 7.46 5.456806
117.07 112.72 4.35 3.787219
115.91 128.52 12.61 10.33861
130.56 119.83 10.73 8.582627
104.49 104.23 0.26 0.249138
103.6 101.55 2.5 2.43736
111.7 116.43 4.73 4.148031
114.93 111.26 3.67 3.245777
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103.5 103.71 0.21 0.202683
98.368 100.01 1.642 1.655509
113.67 116.07 2.4 2.0895
112.74 112.51 0.23 0.204208
158.38 155.5 3.12 1.988148
82.76 79.949 2.811 3.455822
105.43 101.49 3.94 3.80934
110.29 110.75 0.46 0.416214
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Figure 3.5: Bland Altman graph illustrating intra-assay variability in plasma PICP.
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Figure 3.6: Scatterplot illustrating intra-assay variability of Plamsa PI CP.
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3.3.5 Conclusions.
We have demonstrated that all three assays are robust and have limited intra-assay 
variability. This compares fevourably with results published by other centres using 
similar techniques. (Laviades, 1998) (Diez, 1995).
Standardisation of Echocardio graphic Measurement.
3.4.1 Introduction.
It should be accepted that variability is inherent in the technique of echocardiography. 
Therefore every effort was made to limit variability and improve reproducibility. 
Patient position was standardised as much as possible allowing for some variation in 
achieving optimal imaging.
Respiration has been shown to have a significant effect on echocardiographic 
measurement. Therefore all measurements were taken at end expiration.
All measurements were taken as a mean of a minimum of three readings.
All echocardiographic studies and interpretation was performed by one observer (M 
Lindsay)
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3.4.2 Methods
30 subjects from both the hypertensive and normal cohorts were selected at random to 
test intra-observer variability. M Mode and doppler images stored on a digital 
archiving facility (Vingmed Echopac) were re-examined and repeat measurements 
were made by M Lindsay who was blinded to the original results. The digital 
archiving facility allowed re-analysis without access to the original measurements.
The results for the M Mode and Doppler indices are presented below. The results are 
presented in tabular format as a mean of the first and second measurements, the mean 
of the absolute difference between individual measurements, the mean percentage 
difference and the standard error of mean difference.
Results.
3.4.3 M-Mode Measurement. 
Table 3.4: M-mode variability.
Parameter Mean of 
Measureme 
nt 1
Mean of 
measureme 
nt 2
Mean of 
difference of 
Measurement 
s
Mean of % 
difference In 
measurement 
s
Standard 
error of 
mean 
difference.
IVSd (cm) 0.958 0.963 0.049 4.5 0.01
LVPWd
(cm)
0.917 0.878 0.057 6.2 0.01
LVDd
(cm)
4.86 4.76 0.136 2.8 0.02
102
IVSs (cm) 1.48 1.44 0.09 5.2 0.016
LVPWs
(cm)
1.57 1.53 0.13 9.2 0.02
LYDs
(cm)
2.88 2.91 0.16 5.4 0.03
EF (%) 78 76 4 4.6 0.5
FS (%) 40 39 3.5 8.6 0.5
LYM (g) 207 197 14 7 1.7
LYMI
(g/m^)
104 99 8 8 1
3.4.4 Doppler measurement.
Table 3.5: Doppler Variability.
Parameter Mean of 
Measureme 
nt 1
Mean of 
measureme 
nt 2
Mean of 
difference of 
Measurement 
s
Mean of % 
difference In 
measuremen 
ts
Standard 
error of 
mean 
difference.
E velocity 0.74 0.73 0.02 3 0.003
A velocity 0.70 0.69 0.02 3 0.003
E: A ratio 1.08 1.07 0.03 3 0.006
E
Deceîerati 
on time 
(ms)
20 20 2.5 5 0.13
103
IVRT 0.11 0.11 0.01 10 0.001
(sec)
3.4.5 Conclusions.
Despite echocardiography being a technique with inherent variability by using high 
quality imaging machines and standardised techniques we have demonstrated limited 
variability in all measurements.
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Chapter 4 
Investigation o f Collagen Turnover in 
Untreated Essential Hypertension,
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4.1 Abstract
This study was designed to document non-invasively the pathological mechanisms 
responsible for myocardial fibrosis and to assess the clinical utility of plasma markers 
of collagen synthesis and degradation as screening tools for the assessment of fibrosis 
in hypertension. We studied 100 never treated hypertensive patients and 50 normal 
subjects. Echocardiographic assessment was made of LV mass and diastolic filling 
using measurement of E: A ratio, E wave deceleration time (E dec) and isovolumic 
relaxation time (IVRT). The presence of diastolic dysfunction was taken as a 
surrogate marker for the presence of myocardial fibrosis. Plasma carboxy-terminal 
propeptide of collagen type I (PICP), carboxy-terminal telopeptide of collagen type I 
(CITP) and tissue inhibitor of matrix metalloproteinases type I (TIMP-1) were 
measured as markers of collagen synthesis, degradation and inhibition of degradation 
respectively. Plasma TIMP-1 was significantly elevated in the hypertensive cohort 
(358r|g/l Vs 253pg/l p<0.001) as were CITP (5.2pg/l Vs 2.9|ag/l p<0.001) and PICP 
(200pg/l Vs 166pg/l P<0.05). TIMP-1 was significantly elevated in patients with 
diastolic dysfimction (421ï]g/l Vs 283r|g/l p<0.01) and correlated with markers of 
diastolic filling namely E: A ratio (r=0.26 p<0.05) and E Dec (r=0.41 P<0.01). A 
plasma TIMP-1 level of >500rig/l had a specificity of 97% and a positive predictive 
value of 96% in predicting diastolic dysfunction. In patients Avith untreated 
hypertension there is evidence of increased collagen synthesis, degradation and 
inhibition of degradation resulting in fibrosis. Our results demonstrate that Plasma 
TIMP-1 correlates with markers of LV diastolic filling, is predictive of LV 
dysfunction and is a potential non-invasive marker of fibrosis.
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4.2 Introduction.
Left ventricular hypertrophy when defined both by ECG and Echo criteria (Devereux 
1993, Kannel 1970, Kregger 1987) confers an increased cardiovascular risk in 
patients with hypertension independent of blood pressure level. (Dunn 1990)
The two key pathological processes in LVH comprise hypertrophy of the 
myocyte and fibrosis of the interstitium. The fibrosis results fi-om an increase in the 
extracellular matrix and more specifically an increase in the concentrations of 
collagen type I and III (Jalil 1989). This is both a primary fibrosis and a secondary 
reparative fibrosis following myocyte necrosis (Weber 1995). These findings have 
been demonstrated in both post-mortem studies (Rossi 1998, Tanaka 1986) and 
studies utilisiag endomyocardial biopsies (Ciulla 1997).
This accumulation results in a distortion of tissue structure and an increase in 
myocardial stiffiiess. This has pathological significance in the development of 
diastolic dysfunction, as a substrate for ventricular arrhythmias and ultimately in the 
development of systolic dysfunction (Weber 1993).
Due to the pathological significance of fibrosis an understanding of the 
mechanisms involved and a means of accurately monitoring this process is the subject 
of considerable research. Cardiac biopsy is undoubtedly the gold standard in this 
regard but has limitations being an invasive procedure with an appreciable morbidity 
rate in a patient group who do not obviously benefit form this procedure. Thus the 
possibility that the pathophysiological mechanisms central to this process can be 
demonstrated and the process can be monitored non-invasively using markers of
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collagen synthesis and degradation is particularly attractive. Preliminary data is now 
available in this field, most notably from Diez et al who have demonstrated that 
Pro collagen type I carboxy-terminal propeptide (PICP), a marker of collagen 
synthesis, correlates significantly with fibrosis in endomyocardial biopsies (Querejeta 
2000). This work demonstrates a potential role of these markers as surrogates of 
fibrosis and requires further investigation.
We studied a large cohort of never treated hypertensives to achieve two main 
aims. The first was to document non-invasively the pathological mechanisms 
responsible for fibrosis and the second to assess the clinical utility of a number of 
non-invasive markers of fibrosis in this group of patients.
This was achieved firstly by a full cardiac assessment of each patient with 
ECG, echo and ambulatory blood pressure studies. Secondly all patients had a lull 
non-invasive assessment of cardiac fibrosis facilitating a full assessment of the 
pathological mechanisms responsible for fibrosis in hypertension.
Studies have shown that interstitial fibrosis results in LV diastolic dysfunction 
(Brilla 1991, Conrad 1995, Thiedeman 1983) and subsequent regression of this 
fibrosis with ACE-inhibitors results in improvement in parameters of LV diastolic 
filling (Brilla 2000). We therefore took the presence of diastolic dysfunction using 
conventional echo parameters as non-invasive evidence of interstitial fibrosis in our 
study.
4,3 Methods,
Subjects.
The study population consisted of 100 untreated hypertensive patients with 
hypertension diagnosed on 24-hr blood pressure monitoring (mean 24hr BP greater
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than 140/90 mmHG). Patients were enrolled via referral to our hypertension clinic or 
by direct referral from local general practitioners. All patients gave consent and the 
local research ethics committee approved study protocols.
Exclusion criteria comprised conditions that are known to result in myocardial 
or tissue fibrosis. These comprise renal impairment (serum creatinine >130mmol), 
coronary artery disease, secondary hypertension, malignancy of any site, pulmonary 
fibrosis, connective tissue disorders, significant hepatic dysfunction, left ventricular 
systolic dysfunction and COPD.
The control subjects were enrolled through adverts in local press. The normal 
subjects were determined to be normotensive on three standard BP readings and the 
above noted exclusion criteria were applied to this group.
Study conditions.
Patients were studied at a standard time in the morning on one study day. A full 
history and clinical examination was made to identify exclusion criteria and suitability 
for the study.
ECG
All patients received a standard twelve lead ECG. ECGs were analysed for the 
presence of LVH and ST-T changes using standard criteria (Dunn 1990).
Additionally the presence of atrial abnormalities was assessed using pre-defined 
criteria (Tarazi 1966). All ECGs were analysed by a single observer. (M Lindsay).
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24hr Blood Pressure Monitoring.
24 hr BP recordings were taken using a standard oscillometric Spacelab BP monitor. 
Readings were made every 30 minutes through the daytime period and every hour 
over the nocturnal period. Patients must have at least 1 reading per hour, 80% of total 
readings successful and at least a total of 30 readings over the 24-hr period for the 
blood pressure reading to be accepted. All readings taken during this period were 
documented and mean daytime; mean nocturnal and mean 24 hr blood pressures were 
calculated. All taped were analysed by one observer (M Lindsay)
Echocardiographic study.
Patients were studied using a Vingmed CFM800 sonos and a Vingmed System 5 echo 
machine. Examinations were made in a darkened room in the standard left lateral 
position. Measurements were taken according to the guidelines laid down by the 
American Society of Echocardiography (Sahn 1978). Left ventricular mass was 
calculated using the formula validated by Reichek and Devereux (Devereux 1977) 
and indexed for body surface area. An average of at least three measurements was 
taken. Measurement of E: A ratio, E deceleration time and isovolumic relaxation 
times (IVRT) were made in the apical view with a cursor at the mitral valve inflow. 
An average of three measurements was taken at end expiration. A single observer (M 
Lindsay) made all measurements. Using digital archiving images intraobserver 
variability was tested in a blinded fashion. Intra- observer variability was 3.5%, 4%, 
10% and 9% for E: A ratio, E deceleration time, IVRT and calculated left ventricular 
mass index (LVMI) respectively.
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Biochemical Measurements.
Routine biochemical measurements were taken and analysed in the standard fashion. 
All samples were taken at a standard time after thirty minutes in the supine position. 
Samples were immediately centrifuged and the plasma layer removed. The separated 
plasma was divided into three equal aliquots and frozen at minus 80^C. Samples were 
not thawed and refrozen.
We measured plasma PICP as a marker of collagen synthesis, carboxy- 
terminal telopeptide of collagen type I (CITP) as marker of extracellular collagen type 
1 degradation and tissue inhibitor of matrix metalloproteinase type I (TIMP-1) as a 
marker of inhibition of collagen degradation.
Plasma TIMP-1 was measured using a commercially available two stage 
ELISA assay specific for TIMP-1 available from Amersham Pharamaceuticals. All 
samples were analysed in duplicate and intra-assay variability was 4.5%.
Plasma CITP was measured by radio immunoassay using a polyclonal antibody 
direct against CITP (Ristelli 1993). All samples were run in duplicate with the 
intrassay variability calculated as 4.3%.
Plasma PICP was measured using a radioimmunoassay. Samples were run in 
duplicate with the calculated intrassay variability of 4.2%.
Renin and aldosterone were measured using a radioimmunoassay through a 
routine analyser.
Statistical analysis.
The distribution of the collagen markers was tested for normality using the Anderson 
Darling test. CITP was normally distributed whilst both TIMP-1 and PICP were non- 
parametric and thus were log transformed prior to analysis. These continuous
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variables were then analysed using an unpaired two-tailed student’s T test. Data is 
presented in the non-logarithmic format. Correlations were tested using Pearsons 
correlation co-efficient in a logarithmic format as required. Non-continuous variables 
were analysed using a chi-squared test.
4,4 Results,
Baseline characteristics.
I recruited 100 never treated hypertensive subjects and 50 normal subjects. 10 
hypertensive subjects were excluded during screening prior to recruitment and 
analysis (1 subject due to renal impairment, 1 subject due to chronic pulmonary 
disease, 4 subjects due to poor echo views, 2 subjects with LV dysfunction and 2 
subjects with probable angina) and 4 normal subjects were excluded prior to 
recruitment and analysis ( 2 subjects with hypertension and 2 subjects with poor echo 
views).
The baseline characteristics are presented in table4.L±SPM 
As would be expected the hypertensive group had a significantly higher blood 
pressure. There was no significant difference in the age, sex distribution, renal 
function or hepatic parameters between the two groups.
Table 4,1: Baseline criteria ± 1 SEM,
Characteristic Hypertensive Normal P value
Number 100 50
Age 52 51 NS
Smoker (yes/no/ex) 65/20/13 35/7/8 NS
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SexM/F 49/51 23/27 NS
Office systolic BP mmHG 167±2.3 129+2.6 P<0.001
Office diastolic BP mmHG 104±L4 77+2 P<0.001
24Hr Systolic BP mmHG 150±L2
24Hr Diastolic BP mmHG 93+0.87
Urea (pmoFl) 5+0.17 5.2+0.3 NS
Creatinine (pmoFl) 96+2.6 97+2.5 NS
Gamma GT (p/1) 30+3.6 30+5 NS
ECG
Using the defined criteria above 16% of hypertensives and no normals were found to 
have LVH (p=0.002). 14% had ST-T changes and no normals (p<0.01), 5% had LVH 
and strain compared with no normals and 9% had atrial abnormalities compared with 
8% of normals in one of the three criteria used.
Ambulatoiy Blood Pressure.
Readings were on average 90% successful with a mean total of 40 readings over the 
24-hr period. Mean 24 hr blood pressure was 151/93 within this group with an 
average 24hr heart rate of 76/min, Analysis of the daytime readings revealed a mean 
daytime systolic BP of 155mmHG and diastolic of 97mmHG. Daytime heart rate was 
averaged at 77/min. Nocturnal mean systolic BP was 140mmHG and diastolic was 
84mmHG with a mean nocturnal heart rate of 71/min. there was no relationship 
between blood pressure measurements and collagen markers.
113
Echocardiography.
Patients were excluded if poor quality imaging prevented analysis of m-mode and 
Doppler studies.
Results are summarised in the tablc4.2:éS£7l/
Table 4,2: Echocardiographic Parameters ± 1  SEM,
HBP Normals P Value
Number 100 50
IVSd(cm) 1.14+0.02 0.9+0.03 P<0.001
LVPWd (cm) 1.18+0.09 0.9±0.02 P=0.004
LVMI(g/m^) 132+4 97+3 P<0.001
IVRT(sec) 0.123+0.003 0.099+0.004 P<0.001
E;A Ratio 0.968±0.03 1.16+0.03 P<0.001
E wave Deceleration(ms) 22.5+0.8 19.3+0.9 P=0.02
% With LVH 56% 2% P<0.01
There was a significant increase in the septal (1.14cm Vs 0.9cm p<0.001) and 
posterior wall dimensions (1.18cm Vs .9cm p=0.004) within the hypertensive group. 
Calculated left ventricular mass index was also elevated in the hypertensive cohort 
(132g/m^ Vs 97g/m^ p<0.001). All the markers of diastolic filling i.e. IVRT (0.123sec 
Vs 0.099sec p<0.001), E: A ratio (0.97 Vs 1.16 p<0.001) and E wave deceleration 
times (22.5ms Vs 19.3ms p=0.02) were all significantly prolonged in the hypertensive 
cohort. These measurements reveal our hypertensive cohort had demonstrable 
evidence of hypertensive heart disease. The control group had echo parameters within 
the normal range.
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Table 4.3. Collagen markers in Hypertensive subjects.
Parameter Mean Standard Range Standard
Error of Mean Deviation
TMF-I 385 29 83-1704 276
(pg/tnl)
CITP 5.2 0.2 1.8-10.2 1.7
PICP 200 11 72-518 94
TIMP-1
Timp-1 levels were significantly elevated in the hypertensive group as a whole in 
comparison to normal subjects. (385pg/l Vs 253r|g/l p=0.0007) (95% C.I. 71,194) 
{Figure 4.1.)
There was no significant difference in TIMP-1 level in the groups with (n=56) and 
without LVH (n=44)(350T]g/l Vs 450r|g/l p=ns) (95% Cl -20,232). Further analysis 
of the hypertensive group revealed that patients with evidence of diastolic dysfimction 
as defined by an E: A ratio of less than one (n=63) had a significantly higher TIMP-1 
level than patients with hypertension and normal diastolic filling (n=37) (421r)g/l 
vs283r|g/l p=0.005) (95% Cl 44,232). Furthermore there was no significant 
difference in TIMP-1 levels between normal subjects (n=50) and hypertensive 
patients with normal diastolic filling (n=37)(253r|g/l Vs 283pg/l p=ns) (95%CI -  
83^23){Figure 4.2). TIMP-1 levels correlated with indices of diastolic filling namely 
E: A ratio(r=0.26 i^O.05){Figure4.3) and E wave deceleration time (r=0.41 
^<O.Ol){Figure 4.4). There was no relationship between TIMP-1 levels and indices of 
left ventricular mass {Figure 4.5). These findings would suggest that TIMP-1 is a 
marker of fibrosis and is independent of both blood pressure and markers of left 
ventricular mass
115
In regard to the ECG; TIMP-1 levels were found to be higher in patients with 
LVH (n=16) (475pg/l Vs 337pg/l p-0.05)(95% Cl 2,273) and patients with ST-T 
changes (n=14) (530rjg/l Vs 335rig/l p<0.05) (95% Cl 7,396). There was no 
relationship between PICP or CITP levels and the presence or absence of ECG 
changes.
To assess whether an elevated TIMP-1 was truly predictive of diastolic 
dysfunction and hence fibrosis we analysed hypertensive patients with a TIMP- 
l>500r|g/l. We chose this figure as it represented one standard deviation above the 
maximum TIMP-1 level within the normal group and this constituted approximately 
20% of the cohort (19 patients). This cohort had an elevated E wave deceleration time 
and an abnormal E: A ratio confirming the presence of diastolic dysfunction within 
this cohort. This was independent of the confoundmg variables of age, heart rate and 
LVMI. Thus reflecting a group with genuinely inquired diastolic filling. Indeed a 
TIMP-1 level of over 500pg/l in our study showed a specificity of 97% and a positive 
predictive value in predicting diastolic dysfunction of 96%. {Table 4.4)
Table 4,4: Comparison of hypertensive patients with plasma TIMP>SOOrjgA and 
<500Tjg/L±l SEM,
Variable Timp>500î]g/l Timp-K500r}g/l P value
Number 19 81
Age (years) 52+1.5 53+1.5 NS
Heart Rate (/min) 78 +1.1 75+1 NS
LVMI g/m^ 123+3.5 134+4.4 NS
E: A ratio 0.84+0.03 1+0.03 <0.01
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E wave deceleration 27±2.3 20+0.8 <0.05
IVRT 0.13+0.003 0.12+0.003 NS
PICP
Plasma PICP was elevated in the hypertensive group as a whole compared with 
normal subjects. (200pg/l Vs 166pg/l p=0<05) (95% C.I 4,62) There was no 
demonstrable relationship between plasma PICP and any echocardiographic findings 
or blood pressure parameters.
CITP
Plasma CITP was elevated in the hypertensive group compared with normal subjects. 
(5.2pg/l Vs 2.9pg/l p<0.001) (95% C.I 1.73,2.79) There was no relationship between 
CITP and echocardiographic findings or blood pressure measurements.
Relationships between Markers.
There was no significant relationship seen between TIMP-1 and CITP or PICP. 
However a significant positive correlation was demonstrated between CITP and PICP 
as one would expect. (r=0.35, p<0.01)
Renin/aldosterone
Aldosterone levels were significantly elevated in the hypertensive cohort 
(13.7pg/100ml Vs 9.3r|g/100ml p<0.01). Renm levels were also elevated but not 
significantly so. The average Aldosterone/Renin ratio was 1 and no subject had an 
elevated ratio consistent with primary aldosteronism. There was no relationship 
between renin or aldosterone levels with collagen markers or echo parameters.
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4.5 Discussion.
We set out to non-invasively delineate the pathophysiology of fibrosis in 
hypertensive heart disease and to assess the clinical feasibility of using collagen 
markers in this setting. This is by far the largest study to date in this field. We 
enrolled a large cohort of well-characterised never treated hypertensives. We used 
robust assays in standard conditions, which we demonstrated to have acceptable 
reproducibility within our laboratory. It should be accepted that none of the markers 
used in this study are exclusive to the myocardium. Indeed previous studies have 
demonstrated elevation in many fibrotic conditions including pulmonary fibrosis 
(Montano 1989) and hepatic cirrhosis (Li 1994). However we made strenuous efforts 
to exclude confounding conditions enrolling a well characterised cohort without co­
existent conditions leading to fibrosis.
To allow a full assessment of the collagen equilibrium we measured markers 
of collagen synthesis, degradation and inhibition of degradation. We measured PICP 
as a marker of collagen synthesis. PICP would appear to be the most accurate marker 
of collagen synthesis as it is reliably cleaved during the extracellular processing of 
collagen type I unlike other markers such as procollagen type III amino terminal 
peptide (Nimni 1993). As this is excreted via a hepatobiliary route, patients with 
hepatic dysfunction were excluded fi'om this study.
Collagen degradation was assessed by measurement of CITP which is a cross- 
linked telopeptide (Laurent 1987) released ina 1:1 stoichometric fashion when
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collagen type I fibrils are degraded (Ristelli 1993) thus giving an accurate 
measurement of collagen degradation.
Matrix metalloproteinases (MMP) are a family of zinc and calcium 
dependent endopeptidases which play a key role in the degradation of collagen.
MMPs have potent proteolytic activity, which is controlled in a major part by the 
production of specific naturally occurring inhibitors called tissue inhibitors of matrix 
metalloproteinases (TIMP) (Denhardt 1993) .The best characterised is TIMP-1. 
Therefore the measurement of TIMP-1 allows an estimation of inhibition of 
degradation.
We demonstrated an elevation in PICP confirming that collagen synthesis is 
elevated in hypertensive heart disease. These findings are in concordance with 
previous published data (Diez 1995, Querejeta 2000).
We demonstrated a significant increase in TIMP-1 in the hypertensive cohort 
taken as a whole. However, only patients with echocardiographic evidence of 
diastolic dysfunction were found to have a significant elevation in plasma TIMP-1. 
The remaining patients with normal diastolic filling had TIMP-1 levels comparable to 
normal subjects. Furthermore, there was no relationship between TIMP-1 and any 
index of systemic blood pressure or left ventricular mass. Therefore TIMP-1 levels 
are not elevated in hypertension per se but only in patients with diastolic dysfunction 
and fibrosis. This suggests that the synthesis and release of TIMP-1 is independent of 
blood pressure and likely to be dependent on a variety of neurohormonal factors. 
Additionally we have demonstrated that an elevation in measured Timp-1 of greater 
than 500r|g/l is strongly associated with the presence of diastolic function.
One would expect an elevation in TIMP-1 would result in a reduction in 
collagen degradation. However plasma CITP was in fact elevated.
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It is impossible to be sure using non-invasive assessment of the relative roles 
played by fibrosis/degradation and there is no doubt that the interplay between TIMP- 
1 and MMPs is a complex situation. However we have demonstrated that degradation 
of collagen is increased in hypertension. Whether this elevation is sufficient to offset 
the increase in synthesis cannot be determined in this study.
The elevation in TIMP-1 would seem at odds with our finding of increased 
collagen degradation. This need not necessarily be the case. We hypothesise that the 
elevation in measured plasma TIMP-1 although not sufficient to offset the iacrement 
in collagen synthesis is modulating or limiting collagen degradation and thus 
contributing to the development of fibrosis.
Our results are at odds with the only previous work published in this field. In 
this study Diez et al (Laviades 1998) demonstrated an elevation in TIMP-1 levels and 
normal CITP levels. This allowed the authors to conclude that collagen degradation is 
in fact inappropriately low. Differences may be explained by larger numbers in our 
study, our use of plasma rather than serum (plasma now being regarded as preferable 
(Jung 1997, Lein 1997)) and our characterisation of patients by 24hour BP rather than 
solely office blood pressure.
The other aim of our study was to assess each of the collagen markers as 
possible non-invasive markers of fibrosis in hypertensive heart disease. Abnormalities 
in diastolic filling have been shown to precede left ventricular hypertrophy in mild to 
moderate hypertension (Diazumba 1986, Inouye 1985). In addition animal and in vivo 
studies have shown diastolic dysfunction is predominately secondary to fibrosis 
(Matsubara 1997) and is independent of myocyte hypertrophy (Kaito 1996). We 
therefore used diastolic dysfunction as a marker of cardiac fibrosis. CITP and PICP 
do not appear to be accurate predictors. However, we have shown TIMP-1 to be
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independent of blood pressure, to correlate with indices of diastolic filling and have a 
specificity and positive predictive value for diastolic dysfimction of over 95%. A 
measured TIMP-l>500pg/l is an accurate and robust predictor of diastolic 
dysfunction and hence end-organ damage.
Finally we have demonstrated that TIMP-1 levels were significantly elevated 
in patients with ECG ST-T changes. This may suggest that ECG ST-T changes in 
hypertension are indicative of fibrosis.
4.6 Perspectives.
We have demonstrated using non-invasive markers of the collagen equilibrium 
that untreated essential hypertension is characterised by an increase in collagen 
synthesis, degradation and inhibition of degradation. The relative roles played by 
these processes in the resultant fibrosis cannot be determined by this study. Secondly, 
we demonstrated an association between biochemical markers of fibrosis and LV 
diastolic dysfunction in patients with untreated hypertension. In particular we 
identified TIMP-1 as a potential non-invasive marker of fibrosis. Further studies to 
investigate these markers as predictors of risk are needed and if positive will provide 
an important additional marker in the risk assessment of patients with hypertension.
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Figure 4.1: Data Points show plasma TIMP-I concentrations (nanograms/ml) in 
hypertensive patients(HBP)n=100 and normal volunteers (normal)n=SO.
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Figure 4.2: Data points show plasma TIMP-I concentrations (nanograms/ml) in 
hypertensive patients with E:A greater than l(n=37), hypertensive patients with E:A 
ratio of less than 1 (n=63) and normal subjects (n=50).
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Figure 4.3: Scatter plot shows inverse correlation between Log plasma TIMP-1 
concentration and E:A ratio in hypertensive patients. (r=0.26f p<O.OS).
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Figure 4.4: Scatter plot shows a positive correlation between Log plasma TIMP-1 
concentration and E wave deceleration time ( E Dec) in hypertensive patients. 
(r=0.41 p<0.01)
Rgure44
as
as
29
Q. 27
♦ ♦
? 2 S
23
21
1.9
1.7
50 GO0 10 20 30 40
EDec
125
Figure 4.5: Scatter plot shows no correlation (r=0.15 p=ns) between Plasma Log 
TIMP-1 and LVMI (g/m2) in hypertensive patients.
r=0.15
100 150
LVMI (g/m2)
250
126
127
Chapter 5 
Studies o f Biochemical Evidence of
Fibrosis in Veteran Athletes,
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5,1 Abstract 
Background
Studies of exercise induced left ventricular hypertrophy (LVH) in veteran athletes 
suggest the presence of abnormal diastolic filling and incomplete regression of LVH 
on cessation of exercise. We hypothesise that this is secondary to the presence of 
fibrosis. This study was therefore designed to document non-invasively the presence 
of fibrosis in veteran athletes with exercise induced LVH.
Methods and Results.
We recruited a cohort of 45 normotensive elite veteran athletes and 50 normal 
sedentary subjects. Echocardiographic assessment was made of LV dimensions, LV 
mass index, LV systolic and LV diastolic fimction. Plasma carboxyterminal 
propeptide of collagen type I (PICP), carboxy-terminal telopeptide of collagen type I 
(CITP) and tissue inhibitor of matrix metalloproteinase Type I (TIMP-1) were 
measured as markers of collagen synthesis, degradation and inhibition of degradation 
respectively. Veteran athletes had significant elevation in LV dimensions and 
calculated LV mass index confirming the presence of exercise induced LVH in this 
cohort. Diastolic and systolic fimction was normal. Plasma PICP was significantly 
elevated in the cohort of veteran athletes (259pg/l Vs 166pg/l p<0.001) as were CITP 
(5.4pg/l Vs 2.9pg/l p<0.001) and TIMP-1 (350r|g/mlvs253T|g/mlp=0.01). There was 
a further significant elevation of TIMP-1 in athletes with echocardiographic evidence 
of LVH defined as a LVMI>130g/m^ (417r|g/ml Vs 266r|g/ml p=0.02)
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Conclusion.
There is biochemical evidence of disruption of the collagen equilibrium favouring 
fibrosis in veteran athletes with LVH. This may suggest that fibrosis occurs as part of 
the hypertrophic process in veteran athletes.
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5.2 Introduction
Chrome high intensity exercise results in structural cardiac changes in the human 
heart. Henschen first described this at the turn of the last century (Henschen 1889). 
The changes are characterised by an increase in left ventricular chamber dimensions 
and an increase in left ventricular wall thickness (Maron 1986). This is traditionally 
thought to be non-pathological as the hypertrophy regresses on cessation of exercise 
(Ehsani 1978, Maron 1993), it is thought to consist purely of myocyte hypertrophy 
and doppler indices of diastolic filling are on the whole within age matched limits 
(Pellicai 1991).
This situation may however be different in veteran athletes. The limited data 
which is available within this cohort suggests that diastolic function is abnormal and 
more importantly that incomplete regression of LVH occurs on cessation of exercise 
(Miki 1994, Nishimura 1980). Our hypothesis was that these findings could be 
explained by the presence of co-existent fibrosis.
Fibrosis occurring in the context of LVH has important pathological 
consequences (Weber 1993) and therefore the demonstration of fibrosis present in 
exercise induced LVH would be a key finding in our understanding of the clinical 
significance and potential long-term consequences of this process.
The biochemical assessment of fibrosis using collagen markers represents a 
practical, validated and non-invasive method for the assessment of fibrosis in this 
cohort. The clinical utility of this technique in the context of left ventricular
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hypertrophy has been demonstrated by our group (Lindsay 2002) and also most 
notably by Diez et al (Diez 1995, Laviades 1998, Querejeta 2000).
The aim of this study was to demonstrate, using biochemical markers, the 
presence of fibrosis in exercise induced LVH in a cohort of veteran athletes.
5,3 Methods 
Subjects
We enrolled a cohort of veteran athletes. All subjects were active members of the 
Scottish Veteran Harriers club. The subjects were contacted directly and invited to 
attend for the study. All subjects were over the age of 45, had been running for more 
than 10 years at a competitive level, ran more than 30 miles per week and regularly 
competed in elite veteran endurance events.
Exclusion criteria were firstly, conditions that result in left ventricular 
hypertrophy namely hypertension and aortic stenosis. Secondly, conditions that result 
in fibrosis were excluded thus preventing spurious elevation in collagen markers of 
synthesis and degradation. These conditions included renal impairment (serum 
creatinine >130mmol), coronary artery disease, malignancy, pulmonary fibrosis, 
connective tissue disorders, significant hepatic dysfunction, left ventricular systolic 
dysfunction and smoking related airways disease.
A cohort of sedentary normal subjects was recruited via a local advertising 
campaign.
Ethical approval was obtained from the local ethics committee. All subjects 
received a fijll written and verbal explanation of the investigations involved and the 
aims of the study. Written consent was obtained in all cases prior to any investigations 
being performed.
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Study conditions.
Patients were studied at a standard time in the morning on one study day. A foil 
history and clinical examination was made to identify exclusion criteria and suitability 
for the study. Blood pressure was recorded with a mercury syphgmanometer in the 
supine position and an average of three readings was taken.
Echocardiographic study.
Patients were studied using a Vingmed CFM800 sonos or a Vingmed System 5 echo 
machine. Examinations were made in a darkened room in the standard left lateral 
position. Echo measurements were taken in the standard parasternal and apical 
positions. M-Mode measurement was taken in a perpendicular parasternal long axis 
view with the cursor through the tips of the mitral valve leaflets. Measurements were 
taken according to the guidelines laid down by the American Society of 
Echocardiography (Sahn 1978). Left ventricular mass was calculated using the 
formula validated by Reichek and Devereux (Devereux 1977) and indexed for body 
surface area. An average of at least three measurements was taken and images were 
stored on super VHS videotape and on a digital archiving facility (Vingmed 
EchoPac). Ventricular function was assessed via calculation of fractional shortening 
and left ventricular ejection fraction from a left ventricular m-mode. Measurement of 
E: A ratio was made in the apical view with a cursor at the mitral valve inflow. An 
average of three measurements was taken at end expiration and images were stored on 
digital archive.
Standard assessment of valvular function was made.
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A single observer (M Lindsay) made all measurements. Using digital archiving 
images intraobserver variability was tested in a blinded fashion. Intra- observer 
variability was 3.5% and 9% for E: A ratio and calculated left ventricular mass index 
(LVMI) respectively.
Biochemical Measurements.
Routine biochemical measurements were taken and analysed in the standard
fashion.
All samples were taken at a standard time after thirty minutes in the supine 
position. Samples were immediately centrifuged at 3000 rpm for seven minutes and 
the plasma layer removed. The separated plasma was divided into three equal aliquots 
and frozen at minus 80°C. Samples were not thawed and refrozen.
Plasma Tissue Inhibitor of Matrix Metalloproteinase type I (TIMP-1) was 
measured as a marker of inhibition of collagen degradation. Plasma carboxyterminal 
telopeptide of collagen type I (CITP) was measured as marker of collagen degradation 
and plasma carboxyterminal propeptide of collagen type I (PICP) was measured as a 
marker of collagen synthesis.
Plasma TIMP-1 was measured using a commercially available two site ELISA 
assay specific for TIMP-1 available from Amersham Pharamaceuticals. This technique 
is a modified version of that described by Plumpton (1995). All samples were 
analysed in duplicate and intra-assay variability was 4.5%.
Plasma CITP was measured by radioimmunoassay using a polyclonal antibody 
direct against CITP (Ristelli 1993). All samples were run in duplicate with the 
intrassay variability calculated as 4.3%.
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Plasma PICP was measured using a radioimmunoassay. Samples were run in 
duplicate with the calculated intrassay variability of 4.2%.
ECG
All patients received a standard twelve lead ECG with a paper speed of 25mm/sec. 
This was recorded in the supine position on the same study day as the other 
recordings. ECGs were analysed for the presence of LVH and ST-T changes using 
standard criteria (Dunn 1990). Additionally the presence of atrial abnormalities was 
assessed using pre-defined criteria (Tarazi 1966). All ECGs were analysed by a single 
observer. (M Lindsay).
Statistical Analysis.
The distribution of the collagen markers was tested for normality using the Anderson 
-Darling test. All markers were not normally distributed. Therefore results were log 
transformed prior to analysis. Results are presented in the non-logarithmic format. AU 
continuous variables were analysed using unpaired student’s T test. Non-continuous 
variables were analysed using a chi-squared test.
5,4 Results,
45 athletes (5 athletes were excluded prior to recruitment and analysis due to 
hypertension (1 subject), renal impairment (1 subject) and poor echo views (3 
subjects)) and a matched population of 50 normal subjects were recruited. Four 
normal subjects were excluded prior to recruitment and analysis (2 subjects with 
hypertension and 2 subjects with poor echo views).
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Baseline criteria
The two groups were well matched for age, and blood pressure. (Table 5.1)
Table 5.1: Baseline Criteria. (+/- 1 SEM)
Athletes Normal subjects
Number 45 50
Weight (Kg) 68±0.4 71+3.4
Systolic BP (mmHg) 129+2.4 129+2.6
Diastolic BP (mmHg) 77±1.2 77+2
Duration of training (years) 20+1.9 0
Weekly training (miles) 30+2.4 0
Age (years) 52+1.7 52+1.5
ECG findings.
Using the above criteria 36% of athletes and no normal subjects were found to have 
LVH (p<0.001). 11% of athletes and no normal subjects had ST-T abnormalities 
(P<0.01). There was no difference in the incidence of atrial abnormalities There was 
no relationship between any of the coUagen markers and ECG findings. (Table 5.2)
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Table 5.2: ECG findings in athletes and normal volunteers.
ECG Finding Athletes Normal subjects P value
LVH 0% P<0.001
ST~T changes 11% 0% P<0.01
Atrial abnormalities 9% 9% NS
Echocardiography
The cohort of athletes (n=45) had a significant increase in inter ventricular septal 
thickness in diastole (IVSd) 1.17cm Vs 0.9cm (p<0.01), posterior wall thickness in 
diastole (LPWd) 1.1cm Vs 0.91cm p=0.04, left ventricular internal dimension in 
diastole (LVIDd) 5.2cm Vs 4.8cm p<0.001 and left ventricular mass index (LVMI) 
141g/m^ Vs 97g/m^ p<0.001. There was no difference in indices of diastolic filling. 
57% of athletes had an LVMI >130g/m^, demonstrating a high incidence of exercise 
induced LVH amongst our cohort. Relative wall thickness (RWT) was significantly 
elevated amongst athletes 0.42cm Vs 0.37cm p=0.002 suggesting the hypertrophy 
present was concentric in nature. {Table 5.3)
Table 5.3: Echo parameters in athletes and normal volunteers. (+/- ISEM)
Parameter Athletes Normal subjects P value
Number 45 50
IVSd (cm) 1.17+0.03 0.9+0.03 P<0.01
LVIDd (cm) 5.2+0.06 4.8+0.07 P<0.001
LVPWd (cm) 1.1+0.02 0.91+0.02 P=0.04
RWT(cm) 0.42+0.01 0.37+0.01 P-0.002
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LV Mass Index 141+5 97+3 P<0.001
(g/m^)
E: A ratio 1.25+0.07 1.15+0.03 NS
Max e wave vel (m/s) 0.73+0.03 0.73+0.03 NS
Collagen markers.
Table 5:4: Collagen Markers in Athletic cohort.
Parameter Mean Standard 
Error of 
mean
Range Standard
Deviation
TIMPH 350 35 156-1225 233
(pg/ml)
CITP 5.4 0.25 2.8-S.7 1.5
PICP 259 14 152-498 86
TIMP-1
Plasma TIMP-1 was significantly elevated in the cohort of athletes (n=45) compared 
with the normal control group (n=50) (350r|g/ml Vs 253r|g/ml p<0.01) (95%C.I 
20,174), When the cohort of athletes was dichotomised depending on the presence 
(n=25) or absence (n=20) of exercise induced LVH (defined as LVMI greater than 
130g/m^) then the athletes with LVH (n=25) were found to have significantly higher 
plasma TIMP-1 levels (417r|g/ml Vs 266pg/ml p=0.01) (95% C.I 27,276) Figure 5.L 
In fact the athletes without LVH (n=20) had plasma TIMP-1 levels comparable to the 
cohort of normal subjects (n=50) (266r|g/ml Vs 253r)g/ml p=ns) (95% C.I -61,34). 
No relationship was seen with duration or intensity of training {Figure 5.2).
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The cohort of athletes with exercise induced LVH were then fiirther 
characterised to exclude confounding factors, which could explain the elevation in 
TIMP-L Table 5.5 demonstrates that there is no significant difference in any of the 
baseline criteria between the two groups. Therefore, the elevation in TIMP-1 appears 
to reflect a genuine increase in inhibition of collagen degradation in athletes with 
exercise induced LVH.
Table 5.5: Athletes with LVMI>130g/m Vs athletes LVMI<130. (± 1 SEM)
Parameter LVMI>130g/m2 LVMI<130g/m P Value
Number 25 20
Age (years) 52+2.5 53+3 Ns
BSA 1.9+0.02 1.8+0.05 Ns
Systolic BP 129+3 129+5 Ns
(mmHg)
Diastolic BP 77+1 76+3 Ns
(mmHg)
Max E wave 0.75+0.04 0.73+0.03 Ns
velocity (m/s)
E: A ratio 1.4+0.08 1.3+0.13 Ns
TIMP-1 (nanog/ml) 417+57 266+20 0.01
CITP (^ ig/1) 5.6+0.4 5.2+0.3 Ns
PICP (tig/1) 258+19 273+23 Ns
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Duration of 19+2.7 21+3 Ns
training. (Years)
Weekly training. 26+2.7 37+4 0.06
(Miles)
CITP
Plasma CITP levels were significantly elevated in the cohort of athletes (n=45) 
compared with the normal volunteers (n=50) (5.4|xg/l Vs 2.9p,g/l p<0.001) (95% C.I 
1.9,3.1) Figure 5.3. This elevation was demonstrated in athletes with and without 
LVH. No relationship was demonstrated between CITP and LV dimensions, LV mass 
or the duration or intensity of exercise (Figure 5.4 and 5.5).
PICP
Plasma PICP levels were also elevated within the cohort of athletes (n=45) compared 
with normal volunteers (n=50) (259pg/l Vs 166pg/l p<0.001)(95%C.I 60,126) Figure 
5.6. This elevation was demonstrated in athletes with and without LVH. Again no 
relationship was demonstrated between PICP and LV dimensions, LV mass and 
duration or intensity of exercise (Figures 5.7 and 5.8).
5.5 Discussion,
Exercise induced LVH is widely thought to be a benign physiological process. 
However in the absence of prospective controlled studies this cannot be certain. There 
is evidence available that should make us re-examine conventional thinking. Firstly, 
the fact exercise induced LVH regresses on cessation of exercise does not confirm its 
physiological basis. Pathological forms of LVH namely hypertensive heart disease 
and LVH in the context of aortic stenosis all regress on removal of the pathological
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stimulus as does exercise induced LVH. Secondly, follow up studies purporting to 
confirm that athletes have increased a life expectancy are flawed, as these studies 
have not been controlled for major cardiovascular risks such as smoking (Sama
1993). Finally, post-mortem studies have revealed an incidence of 18% of idiopathic 
LVH in sudden cardiac death in athletes (Maron 1980). Clearly this limited data 
cannot confirm a causative role of LVH however should raise some concern.
The issue of the possible pathological role of exercise induced LVH in veteran 
athletes is even less well defined. The studies that are available reveal some 
concerning findings, namely, that middle-aged athletes are more prone to developing 
ECG abnormalities, prominent hypertrophy and may have slightly depressed LV 
function (Nishimura 1980). In addition diastolic function may be abnormal and 
regression of LVH after 2 years of cessation of exercise may be incomplete (Miki
1994).
It was this finding of incomplete regression of LVH in veteran athletes which 
was the stimulus to our study. If regression was incomplete than this may reflect 
pathological abnormalities. Namely, that in addition to the accepted myocyte 
hypertrophy there may in fact be a degree of interstitial fibrosis. Interstitial fibrosis 
occurring in the context of left ventricular hypertrophy is an important pathological 
entity resulting in the development of diastolic dysfimction and acting as a substrate 
for ventricular arrhythmias (Weber 1993). Therefore the demonstration of fibrosis 
would be an important finding in allowing us to understand the clinical significance 
and consequences of exercise induced LVH.
Biochemical assessment of the collagen equilibrium is now possible. PICP, 
which is cleaved on incorporation of procollagen type I into the collagen helix and has 
been shown to be a non-invasive measure of fibrogenesis (Niroini 1993, Savolainen
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1984). CITP which is cleaved when collagen type I is degraded has been shown to be 
a measure of collagen degradation (Ristelli 1993, Eriksen 1993). Finally TIMP-1 
which is a naturally occurring specific inhibitor of Matrix Metalloproteinases, which 
are the rate limiting step in collagen degradation has, been shown to be a measure of 
inhibition of collagen degradation (Demhardt 1993). Therefore by measurement of 
PICP, CITP and TIMP-1 we achieved an accurate biochemical assessment of both 
sides of the collagen equilibrium. The clinical utility of biochemical markers of 
fibrosis in the context of LVH has been previously demonstrated by our group 
(Lindsay 2002). These markers are not specific to the myocardium therefore care was 
taken to exclude individuals with conditions that may result in fibrosis through other 
means.
Care was taken to enrol a cohort of elite athletes who would have exercise 
induced cardiovascular changes. This was achieved using strict inclusion criteria. All 
echo parameters of LV mass were significantly increased and 57% of our cohort had a 
LVMI greater than 130g/m^.
Our results demonstrate that in elite veteran athletes there is biochemical 
evidence of disruption of the collagen equilibrium in comparison with a matched 
cohort of sedentary control subjects. Taking the cohort of athletes as a whole we have 
demonstrated a significant increase in collagen synthesis as assessed by an elevation 
in PICP, an increase in collagen degradation as assessed by an elevation in CITP and 
an increase in inhibition of degradation as assessed by an elevation in TIMP-1. Of 
more significance is the finding that athletes with echo evidence of exercise induced 
LVH (LVM1> 13 Og/m )^ had a further statistically significant elevation in TIMP-1. 
Indeed TlMP-1 was only elevated in athletes with LVH; the remaining athletes having 
TIMP-1 levels comparable to normal. Therefore, there only appears to be an elevated
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inhibition of degradation (TIMP-1) amongst athletes with LVH. This disruption of the 
collagen equilibrium amongst athletes with LVH, characterised by inhibition of 
collagen degradation, would favour the development of fibrosis. This contrasts with 
PICP and CITP, which were elevated throughout the cohort of athletes irrespective of 
the presence of LVH.
These findings suggest that increments in collagen synthesis and degradation 
occur at an early stage in the development of exercise induced cardiovascular 
adaptation. Whereas inhibition of collagen degradation occurs only in more advanced 
stages of cardiovascular adaptation associated with established exercise induced LVH. 
Within the setting of exercise induced LVH, increments in collagen degradation 
would favour the development of fibrosis. The finding of elevated TIMP-1 amongst 
athletes with LVH cannot be explained by confounding factors and represents a 
genuine elevation. We can therefore conclude that in veteran athletes with LVH there 
is a disruption of the collagen equilibrium characterised by an increased inhibition of 
collagen degradation favouring the development of fibrosis.
It should be noted that the cohort of veteran athletes studied did not 
demonstrate evidence of diastolic dysfimction which one might expect in the context 
of myocardial fibrosis. There are several possible explanations for this. Diastolic 
dysfimction is a complex process, which has been best described in the context of 
hypertensive left ventricular hypertrophy. However, the factors involved in the 
development of fibrosis in hypertensive heart disease are clearly different from those 
important in exercise induced LVH. Namely, in hypertensive heart disease there are 
chronic elevations in the effector hormones of the renin angiotensin system, which are 
central to the development of fibrosis and independent of myocyte hypertrophy 
(Weber 1994). Fibrosis, if present in exercise induced LVH, is likely to be mediated
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by different factors and may relate to the chronic loading of regular high intensity 
exercise. In addition, due to the complex cardiovascular adaptive changes which 
occur in exercise induced LVH the development of diastolic dysfunction secondary to 
fibrosis may occur much later in this process than is seen in hypertensive heart 
disease. Therefore the absence of diastolic dysfimction in this cohort of athletes does 
not mean the absence of fibrosis.
Other possible explanation for our findings would be, firstly, that the changes 
in the collagen equilibrium demonstrated, merely reflects remodelling associated with 
increments in LV mass. However if this were the case then one would expect a direct 
correlation between increasing LV mass and increments in PICP, CITP and TIMP-I. 
This is not seen. There are no correlations with markers of the collagen equilibrium 
and any echo assessment of left ventricular mass. Furthermore TIMP-1 levels are only 
elevated in the presence of documented LVH. Therefore, we feel this explanation can 
be discounted. Secondly, it must be accepted that the markers used have wider 
biological roles. It is conceivable that the elevations demonstrated may relate, in part, 
to these roles. For example TIMP-1 was first described as a haemopoetic-stimulating 
factor and, as such, may be stimulated by aerobic training (Gasson 1985).
In conclusion, our results demonstrate that there is biochemical evidence of 
disruption of the collagen equilibrium favouring fibrosis in veteran athletes with 
LVH. This suggests fibrosis may occur as part of the hypertrophic process of exercise 
induced LVH m veteran athletes. This would explain incomplete regression of LVH 
in this cohort and may suggest that this process is pathological.
144
Figure 5.1: Data points show plasma TIMP-1 concentrations (nanograms/ml) in 
athletes with L VMI>130g/m2 (n=25), athletes with L VMI<130g/m2 (n=20) and 
normal subjects (n=50).
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Figure 5.2: Scatter plot show no significant correlation between Log Plasma
TIMP-1 and intensity of weekly training (miles per week)(r=0.12 p=ns) in the
athletic cohort.
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Figure 5.3: Data points show plasma CITP concentrations (micrograms/l) 
in Athletes(n=45) and normal volunteers (normals).
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Figure 5.4: Scatter plot show no significant correlation between Log Plasma
CITP and LVMI (g/m )^ (r=0.02 p=ns) in the athletic cohort.
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Figure 5.5: Scatter plot shows no significant correlation between Log plasma
CITP and intensity of weekly training (miles per week) (r=0.1 p=ns) in the
athletic cohort.
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Figure 5.6: Data points show plasma PICP concentrations (micrograms/l) 
in Athletes (n=45) and normal volunteers(normals).
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Figure 5.7: Scatter plot shows no significant correlation between Log plasma
PICP and LVMI (g/m )^ (r=0.2 p=ns) in the athletic cohort.
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Figure 5.8: Scatter plot show no correlation between Log plasma PICP and
intensity of weekly training (miles per week) (r=0.18 p=ns) in the athletic cohort.
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C h a p t e r  6 :
S t u d i e s  o f  b i o c h e m i c a l  e v i d e n c e  o f
f i b r o s i s  i n  “ W h i t e  c o a t ”  a n d  m i l d
h y p e r t e n s i o n .
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6.1 Abstract.
The pathological significance of white coat hypertension and the BP level target organ 
damage occurs remains unclear. We attempted to fiirther this debate by studying the 
presence of fibrosis, using biochemical markers, in patients with stage I and white 
coat hypertension. We enrolled 50 never treated hypertensives with an ofiBce BP 
>140/90mmHg and a mean ambulatory BP <140/90mmHg. The cohort was divided 
into three groups according to ambulatory BP. Group l(n=25): mean daytime systolic 
BP > 140mmHg, Group 2 (n=13) mean daytime systohc BP 135-140/90mmHg and 
Group 3 (n=12): mean daytime BP < 135/85mmHg. Echocardiographic and 
electrocardiograhic assessment was made. Plasma carboxy-terminal propeptide of 
collagen type I (PICP), carboxy-terminal telopeptide of collagen type I (CITP) and 
tissue inhibitor of matrix metalloproteinases type I (TIMP-1) were measured as 
markers of collagen synthesis, degradation and inhibition of degradation respectively. 
Significant elevations in LV mass index were demonstrated in group 1 and 2. TIMP-1 
was not significantly elevated in any of three groups. PICP was elevated in group 
l(217pg/l Vs 167pg/l P<0.05) and CITP was significantly elevated in group l(4.5p,g/l 
Vs 2.9pg/l p<0.01), group2 (5pg/l Vs 2.9pg/l p<0.01) and Group3 (S.lpg/l Vs 2.9jLtg/l 
p<0.05) when compared to normal volunteers. Therefore, we have demonstrated 
abnormalities in collagen synthesis and degradation in patients with white coat 
hypertension. This suggests that early qualitative changes in the extracellular matrix 
of the cardiovascular system occur in patients with white coat hypertension including 
subjects with a normal ambulatory blood pressure recording by current definitions.
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6,2 Introduction,
White coat hypertension is term now commonly used to describe individuals with 
persistently elevated office blood pressure readings but who have a normal 
ambulatory BP (Mancia 1987). The incidence of this condition varies markedly 
depending on the definition used. Pickering et al (1988) estimated that 20% of 
individuals thought to have mild or stage 1 hypertension had “white coat 
hypertension”. Data fi*om the Italian PAMELA study revealed a prevalence of 
between 7% to 12% in a randomly selected population and 12% upwards in untreated 
individuals vdth stage I or II hypertension (Sega 2001).
The prognosis of patients with white coat hypertension is not clear despite 
several studies having addressed this issue directly. The results of theses studies have 
varied considerably with some authors reporting that white coat hypertension is 
associated with an adverse outcome (Palatini 1988, Pierdomenico 1995, Glen 1996) 
whilst others report no positive findings (Gosse 1993, Hoegholm 1993, Cavallini 
1995). The variations in results can be explained to some extent by variations in 
definition of white coat hypertension. Namely a cohort with a higher blood pressure 
will by definition have a higher incidence of end-organ damage.
Most of the published studies have attempted to demonstrate the presence of 
left ventricular hypertrophy as an end-point (Gosse 1993, Hoegholm 1993, Cavallini 
1995), however, none have addressed the presence of myocardial fibrosis in this 
cohort. Despite the fact that it has become increasingly apparent that it is not only the 
quantity i.e. left ventricular mass but also the quality of the left ventricle structure 
which is important. Myocardial fibrosis occurs as part of the hypertrophic process in 
hypertension (Ciulla 1997) and has a key pathological role in the development of
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diastolic dysfunction and subsequent systolic dysfunction in hypertension and also as 
a substrate for ventricular arrhythmias (Weber 1993).
Therefore the demonstration of fibrosis or a disruption in the normal collagen 
equilibrium within a cohort of white coat hypertensives would be an important finding 
in the ongoing work to determine the pathological nature and clinical consequences of 
white coat hypertension. A large study involving myocardial biopsies of an otherwise 
well population of white coat hypertensives would not be feasible. However 
increasingly biochemical markers of collagen metabolism have been used in the 
context of hypertension to help us determine the mechanisms of responsible for 
fibrosis and perhaps provide a biochemical means of diagnosis. This has been 
^çrqopsltqlpd in pubhshed work by our group and others (Laviades 1998, Lindsay 
2002).
Therefore the aim of this study was to demonstrate evidence of fibrosis or 
disruption of the collagen equilibrium within a well-defined cohort of patients with 
white coat hypertension.
6.3 Methods,
Subjects.
The study population consisted of 50 never treated hypertensives who had three office 
blood pressure measurements greater than 140/90mmHg with a subsequent mean 24hr 
ambulatory blood pressure reading of less than 140/90mmHg. Patients were enrolled 
via referral to our hypertension clinic or by direct referral fi'om local general 
practitioners. All patients gave consent and the local research ethics committee 
approved study protocols.
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Prior to analysing our results, we chose to divide and analyse our cohort according to 
predefined blood pressure parameters. The reasons for this were twofold. Firstly, as 
the cohort would contain a spectrum of blood pressures ranging fi'om stage I 
hypertension to blood pressures currently defined as normal. We thought it important, 
for the vafidity of our results, to ensure that any positive result obtained was not 
merely driven by subjects with stage I hypertension. Secondly, by dividing the cohort 
into pre-defined blood pressure parameters we were able to define at what blood 
pressure levels changes in the collagen equihbrium occur.
The cohort was therefore divided and analysed in three groups. Group 1 consisted of 
subjects with a mean daytime systolic BP of >140mmHg (n=25). Group 2 consisted 
of subjects with a mean daytime systolic BP of 135-140/90mmHG (n=13). Group 3 
consisted of all subjects with a mean daytime BP of less than 135/85mmHG (n=12).
As the collagen markers used are not specific for myocardial collagen; 
conditions, which result in fibrosis of other organs, or conditions, which result in left 
ventricular hypertrophy of other causes, were excluded. These comprise aortic 
stenosis, renal impairment (serum creatinine >130p,mol/l), coronary artery disease, 
secondary hypertension, malignancy of any site, pulmonary fibrosis, connective tissue 
disorders, significant hepatic dysfimction, left ventricular systolic dysfunction and 
chronic obstructive pulmonary disease.
50 control subjects were enrolled through adverts in local press. The normal 
subjects were determined to be normotensive on three standard BP readings 
(<140/90mmHG) and the above noted exclusion criteria were apphed to this group.
Six hypertensive subjects were excluded prior to analysis and recruitment. 
Four had poor echo views, one patient had renal impairment and one patient had 
symptomatic coronary disease. Four normal subjects were excluded prior to
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recruitment and analysis (2 subjects with hypertension and 2 subjects with poor echo 
views).
Study conditions.
Patients were studied at a standard time in the morning on one study day. A fixll 
history and clinical examination was made to identify exclusion criteria and suitabihty 
for the study.
ECG
All patients received a standard twelve lead surface ECG which were analysed for the 
presence of LVH, ST-T changes and atrial abnormahties using standard criteria (Dunn 
1990, Tarazi 1966). All ECGs were analysed by a single observer. ( M Lindsay).
24hr Blood Pressure Monitoring.
24 hr BP recordings were taken using a standard oscillometric Spacelab BP 90217 
monitor. The monitor was attached to the non-dominant arm and three test readings 
were performed to ensure satisfactory recording. The monitor was set to make a 
recording every 30 minutes through the daytime period and every hour over the 
nocturnal period. Patients must have at least 1 reading per hour, 80% of total readings 
successful and at least a total of 30 readings over the 24-hr period for the blood 
pressure reading to be accepted. All readings taken during this period were 
documented and mean daytime, mean nocturnal and mean 24 hr blood pressures were 
calculated. All tapes were analysed by one observer (M Lindsay).
Echocardiographic study.
Patients were studied using a Vingmed CFM800 sonos and a Vingmed System 5 echo 
machine. Examinations were made in a darkened room in the standard left lateral
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position. Measurements were taken according to the guidelines laid down by the 
American Society of Echocardiography(Sahn 1978). Left ventricular mass was 
calculated using the formula vahdated by Reichek and Devereux and indexed for 
body surface area (Devereux 1977). An average of at least three measurements was 
taken. Measurement of E: A ratio, E wave deceleration time and isovolumic 
relaxation times (IVRT) were made in the apical view with a cursor at the mitral valve 
inflow. An average of three measurements was taken at end expiration. A single 
observer (M Lindsay) made all measurements. Using digital archiving images 
intraobserver variability was tested in a blinded fashion. Intra- observer variabihty 
was 3.5%, 4%, 10% and 9% for E: A ratio, E deceleration time, IVRT and calculated 
left ventricular mass index (LVMI) respectively.
Biochemical Measurements.
Routine biochemical measurements were taken and analysed in the standard fashion. 
All samples were taken at a standard time after thirty minutes in the supine position in 
a darkened room. Samples were immediately centrifuged at 3000rpm for seven 
minutes and the plasma layer removed. The separated plasma was divided into three 
equal ahquots and frozen at minus 80“C. Samples were not thawed and refi*ozen.
To obtain an accurate biochemical assessment of the collagen equilibrium 
three markers were used. We measured plasma carboxy-terminal propeptide of 
collagen type I (PICP) as a marker of collagen synthesis, carboxy-terminal telopeptide 
of collagen type I (CITP) as marker of extracellular collagen type 1 degradation and 
tissue inhibitor of matrix metaUoproteinase type I (TIMP-1) as a marker of inhibition 
of collagen degradation.
Plasma TIMP-1 was measured using a commercially available two stage 
ELISA assay specific for TIMP-1 available from Amersham Pharmaceuticals. This
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technique is a modified version of that described by Plumpton (1995). All samples 
were analysed in duplicate and intra-assay variability was 4.5%.
Plasma CITP was measured by radioimmunoassay using a polyclonal antibody 
direct against CITP (Ristefii 1993). All samples were run in duplicate with the 
intrassay variability calculated as 4.3%.
Plasma PICP was measured using a radioimmunoassay. Samples were run in 
duplicate with the calculated intrassay variability of 4.2%.
Statistical analysis.
The distribution of the collagen markers was tested for normality using the Anderson 
Darling test. CITP was normally distributed whilst both TIMP-1 and PICP were non- 
parametric and thus were log transformed prior to analysis. These continuous 
variables were then analysed using an unpaired two-tailed student’s T test. Data is 
presented in the non-logarithmic format. Correlations were tested using Pearson’s 
correlation co-efficient in a logarithmic format as required. Non-continuous variables 
were analysed using a chi-squared test.
6,4 Results,
Baseline Characteristics.
The results are presented in Table 1± 1SEM.
Table 6.1: Baseline Criteria ± 1 SEM.
Variable HBP Normals P value
Number 50 50
Age (years) 42
Sex (male/female) 26/24 
Smoking 12/36/2
(yes/no/ex)
Systolic BP 148+1.5
(mmHg)
Diastolic BP 96+1
(mmHg)
52
23/27
35/7/8
129+2.6
77+2
<0.01
NS
NS
<0.01
< 0.01
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Urea (|Limol/L) 4.6+0.2 5.2+0.3 NS
Creatinine 87±2 97+2.5 NS
(pmol/L)
There is no difference in sex distribution, smoking habits or renal function. The group 
of white coat hypertensives is however significantly younger. We do not feel that this 
affects the vafidity of our results. As one would expect office blood pressure readings 
are significantly higher amongst the cohort of subjects with white coat hypertension. 
ECG.
ECG were analysed using the above referenced criteria. 2% of white coat 
hypertensives and no normals had LVH. 14% of white coat hypertensives had ST-T 
change and no normal subjects (P<0.01). The presence of ST-T change was not 
related to blood pressure level. 8% of both groups had atrial abnormalities.
Ambulatory Blood Pressure.
Readings were on average 85% successful with 37 individual readings taken over an 
average of a 25hr period. Mean 24hr blood pressure for the cohort of white coat 
hypertensives was 131/81mmHG. Mean daytime blood pressure was 136/87mmHG 
with an average daytime heart rate of 80/min. Mean nocturnal blood pressure was 
119/73mmHG with an average nocturnal heart rate of 70/min. The strict definition as 
to what represents normal blood pressure is variable. We therefore analysed our 
cohort of white coat hypertensives at three pre-defined blood pressure levels as 
described above.
Echocardiography.
Patients were excluded if poor quality imaging prevented analysis of m-mode and 
doppler studies.
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Results are summarised in the table 2±SEM
Table 6.2: Echocardiographic parameters ± 1 SEM,( * p<0.01 and ♦ p<0.05 Vs 
Normal Volunteers.)
Parameter Group 1 Group 2 Group 3 Normal
Volunteers
Number 25 13 12 50
IVSDd (cm) 1.08+0.05* 1.09+0.064 1.00+0.05 0.90+0.03
LVPWd (cm) 1.05+0.03* 1.09+0.04* 1.00+0.04 0.90+0.02
LVMI (g/m2) 112+54 121+84 103+5 97+3
E: A ratio 1.24+0.07 1.1+0.08 1.15+0.10 1.15+0.03
E Dec (ms) 17.8+1.0 16.1+1.4 18.1+1.0 19.3+1.0
IVRT (sec) 0.1+0.004 0.1+0.01 0.1+0.004 0.09+0.003
The echo data was analysed at three pre-defined blood pressure cut-offs as defined 
above. Group 1 (n=25) had a significant increase in interventricular septal thickness in 
diastole (IVSd) (1.08cm Vs 0.90cm p<0.01), left ventricular posterior wall thickness 
m diastole (LVPWd) (1.05cm Vs 0.90cm p<0.01) and left ventricular mass index 
(LVMI) (112g/m2 Vs 97g/m2 p<0.05) when compared with the group of normal 
volunteers (n=50). There was no difference in any of the indices of diastolic filling, 
namely, E: A ratio (1.24 Vs 1.15 p=ns), E Dec (18ms Vs 19ms p=ns) and IVRT 
(0.1 sec Vs 0.1 sec p=ns). Group 2 (n“ 13) again demonstrated an increase in IVSd 
(1.09cm Vs 0.90cm p<0.05), LVPWd (1.09cm Vs 0.90cm p<0.01) and LVMI 
(121g/m2 Vs 97g/m2 p<0.05) in comparison with the group of normal volunteers 
(n=50). There was again no difference in the indices of diastohc filling. However the 
cohort with a mean daytime blood pressure of less than 135/85mmHg (n=12) 
demonstrated no significant difference in IVSd (0.98cm Vs 0.90cm p=ns), LVPWd 
(0.99cm Vs 0.91cm p=ns) or LVMI (103g/m2 Vs 97g/m2 p=ns) when compared to 
the normal volunteers (n=50). There was no difference in indices of diastolic filling.
162
Collagen markers.
TIMP-1
TIMP-1 was not significantly elevated in group I (n=25)(307ng/ml Vs 253ng/ml 
p=ns) (95%C.I -32,140), group 2 (n=13)(282ng/ml Vs 253ng/ml p=ns) (95%C.I -  
42,100), group 3 (n=12)(315ng/ml Vs 253ng/ml p=ns) (95% C.I -67,192) or when the 
cohort was analysed as a whole (n=50) (290ng/ml Vs 253ng/ml p=ns) (95% C.I -  
13,88) when compared with normal volunteers (n-50). There was no relationship 
between TlMP-1 and blood pressure, markers of LV mass or indices of diastolic 
filling.
CITP
CITP was significantly elevated in group 1 (n=25)(4.5|iig/l Vs 2.9pg/l p<0.01)(95%
C.I 0.41,2.7), group 2 (n=13)(5pg/l Vs 2.9pg/lp<0.01)(95% C.I 0.69,3.35), group 3 
(n=12)(5.1jLig/l Vs 2.9gg/l p<0.05)(95% C.I 1.09,2.41) and when the cohort was 
analysed as a whole (n=50) (4.8pg/l Vs 2.9gg/l p<0.01)(95%C.I 1.04,2.64) when 
compared with normal volunteers (n=50). These findings are demonstrated on Figures 
6.1,6.2,6.3,and 6.4. This elevation was consistent amongst all the groups and 
independent of any blood pressure variable. There was no relationship between CITP 
and any of the markers of LV mass or indices of diastohc filling.
PICP
PICP was significantly elevated in group 1 (n=25)(217jiig/l Vs 166pg/l p<0.05)(95% 
C.I 1,98.7) (figure 6.S) and when the cohort was analysed as a whole (n=50) (214pg/l 
Vs 166pg/l p<0.01) (95% C.I 12,81.7). However no significant elevation was 
observed in group2 (n=13) (214p,g/l Vs 166pg/l p=ns)(95%C.I -32,127.8) or group 3 
(n=12)(205jLig/l Vs 166|rg/l p=ns)(95%C.I -14,91) when compared with normal
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volunteers (n=50). There was no relationship between PICP and blood pressure, 
markers of LV mass or indices of diastolic filling.
6,5 Discussion.
As described above the pathological significance of white coat hypertension remains 
uncertain. The first and perhaps the key issue is the strict definition of what classes as 
white coat hypertension remains variable. There is now a consensus that an office 
blood pressure greater than 140/90mmHg is abnormal. The subsequent definition of a 
normal ambulatory blood pressure remains contentious. Almost all the large studies 
have used different definitions and therefore have different results regarding incidence 
of long-term sequelae and incidence of target organ damage. For this reason, in 
addition to analysing our cohort as a whole, we chose to analyse our cohort at three 
pre-defined blood pressure levels. The first being a mean daytime systolic BP of 
greater than 140mmHg. Most experts would agree that this group would consist 
predominately of subjects with stage I hypertension. The second cut-off was a mean 
daytime systolic BP 135-140mmHg and finally a cut-off of a mean daytime of 
<135/85mmHg, which most consensus statements would class as normal (JNC VI).
The aim of our study was to demonstrate the presence of target organ damage 
among this cohort and, if possible, to define the level of blood pressure at which this 
became demonstrable. Most previous studies have looked for echocardiographic 
evidence of an increase in left ventricular mass or impairment in diastolic filing for 
this purpose (Gosse 1993, Hoegholm 1993, Cavallini 1995). However no previous 
work has addressed the issue of qualitative change in left ventricular structure in the 
form of fibrosis. This is recognised as a key pathological component of hypertensive 
left ventricular hypertrophy. We therefore undertook to study the presence or absence
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of fibrosis in this cohort. We achieved this by the use of biochemical markers of
collagen metabolism.
To allow a fuU assessment of the collagen equilibrium we measured 
markers of collagen synthesis, degradation and inhibition of degradation. Plasma 
PICP was measured as marker of collagen synthesis. This peptide is the most accurate 
marker of collagen synthesis as it is reliably cleaved during the extracellular 
processing of collagen type I unlike other markers such as procollagen type III amino 
terminal peptide (Nimni 1993). As this is excreted via a hepatobiliary route, patients 
with hepatic dysfunction were excluded fi'om this study.
Collagen degradation was assessed by measurement of CITP, a cross-linked 
telopeptide released in a 1:1 stoichometric fashion when collagen type I fibrils are 
degraded thus giving an accurate measurement of collagen degradation (Ristelli 
1993).
Matrix: metalloproteinases (MMP) are a family of zinc and calcium 
dependent endopeptidases, which play a key role in the degradation of collagen.
MMPs have potent proteolytic activity, which is controlled in a major part by the 
production of specific naturally occurring inhibitors called tissue inhibitors of matrix 
metalloproteinases (TIMP) .The best characterised is TIMP-1. Therefore the 
measurement of TIMP-1 allows an estimation of inhibition of degradation (Dernhardt 
1993).
The limitations of this study should be accepted. Firstly, none of the above 
markers are specific for myocardial collagen introducing potential confounding 
results. However, care was taken to exclude any conditions that would result in 
myocardial fibrosis of another aetiology or end-organ fibrosis elsewhere. Secondly, 
the blood pressure parameters used do not represent a strict definition of “White coat”
165
hypertension under current British Hypertension Society Guidelines. However, 
guidelines have changed since this study was conceived and recruited and hence the 
variance with current recommendations.
Our results demonstrate some very illuminating findings. Firstly it is notable 
that even within the cohort of subjects that a mean daytime systolic BP of 135- 
140mmHg there is still a significant increase in left ventricular dimensions and 
calculated left ventricular mass index when compared with the cohort of normal 
subjects. The demonstration of an increment in LV mass at such a low level is 
surprising. There was no abnormahty in diastohc filling in any of three groups.
Analysis of the coUagen markers allows us further insight. There was no 
significant elevation in inhibition of collagen degradation (TIMP-1) in any of the 
cohorts. This would be consistent with our previous pubhshed work on collagen 
markers in sustained hypertension, which demonstrated that TIMP-1 was a marker of 
diastohc dysfunction and only elevated in the presence of abnormal diastohc filling 
(Lindsay 2002). However, the positive and important findings fi'om this study are 
twofold. Firstly was the finding of elevated coUagen synthesis in Group 1. As noted 
above this group had a mean 24hr BP of less than 140/90mmHg and a daytime 
systohc BP of greater than 140mmHg. Most experts would agree that blood pressure 
at this level is abnormal and represents stage I hypertension but nonetheless it is a 
notable finding that cohagen synthesis is stimulated in the context of mild 
hypertension. The second important finding was the demonstration of elevated 
coUagen degradation amongst aU groups. This may not have been too surprising if this 
were limited to group 1, where we have demonstrated elevated coUagen synthesis and 
which contains subjects with stage I hypertension. However, even the cohort with a 
daytime BP of less than 135/85mmHg there was a significant elevation in coUagen
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degradation when compared to the normal cohort (5.1pg/l Vs 2.9pg/l p<0.01). 
Therefore, using a strict definition of white coat hypertension, namely, an office blood 
pressure of greater than 140/90mmHg and a mean daytime ambulatory blood pressure 
of less than 135/85mmHg there is still demonstrable evidence of disruption of the 
collagen equilibrium.
Clearly, this study using non-invasive biochemical markers does not prove 
definitively that fibrosis is present in white coat hypertension. However, we have 
demonstrated a disruption of the collagen equilibrium with an increments in collagen 
degradation at aU levels and an increment in collagen synthesis within group 1 of our 
cohort. These findings echo those demonstrated in sustained hypertension of which 
fibrosis is an accepted part. Therefore this allows us to hypothesise that changes in 
extracellular matrix leading to fibrosis occur in white coat hypertension.
Furthermore, this study allows us to hypothesise about the temporal 
relationship of collagen synthesis, degradation and inhibition of degradation in 
hypertension and the resulting fibrosis. It would appear that abnormalities in collagen 
degradation are the initial pre-cursor to the development of fibrosis occurring at 
modest elevations in blood pressure previously regarded as normal, collagen synthesis 
is stimulated in borderline and stage I hypertension and inhibition of degradation is 
only demonstrated when fibrosis is established and demonstrable by non-invasive 
means for example diastohc dysfunction on echo.
Therefore, in conclusion, we have demonstrated disruption of the collagen 
equihbrium with increased cohagen synthesis and degradation in patients with white 
coat hypertension. We have shown these changes occur at blood pressure levels 
currently considered to faU within the normal range. These findings suggest that 
quahtative changes occur in the myocardium/vasculature in white coat hypertension at
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a very early stage. This has important implications in the ongoing debate regarding 
the clinical consequences of white coat hypertension, at what levels should 
hypertension be treated and also raises questions about what truly represents a normal 
ambulatory blood pressure in patients with elevated office readings.
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Figure 6.1. Data points show CITP concentrations (micrograms/i) in the cohort of 
hypertensives (n=50) as a whole and normal volunteers.
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Figure 6.2: Data points show plasma CITP (mlcrograms/l) In subjects with a mean daytime systolic
BP of >140mmHg (group 1) (n«25) and normal subjects.
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Figure 6.3: Data points show plasma CITP levels (micrograms/L) In subjects with a mean daytime
systolic BP of 135-140mmHg (group 2)(n=13) and normal subjects.
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Figure 6.4: Data points show plasma CITP (micrograms/l) in subjects with a mean daytime BP
<135/85mmHg (group3) (n=12) and normal subjects.
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Figure 6.5: Data points show plasma P1CP(micrograms/l) in subjects with a mean daytime systolic
BP of > 140mmHg (n=25) and normal subjects.
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Chapter 7 
Summary and conclusions.
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The results of any clinical investigations rely on the validity and reproducibility of the 
methods used. It was therefore key to this thesis that the assays used and techniques 
employed were reliable and reproducible. To ensure this, we performed extensive 
validation and reproducibility experiments on all three assays prior to any clinical 
studies. The results are documented in Chapter 3 and reveal intra-assay variability of 
less than 5% for all three assays, which compares very favourably with previous 
published work.
Echocardiography is a central technique in this thesis and has undoubted 
inherent variability. Echo studies were performed by one operator (M Lindsay) using 
a standardised protocol in an effort to limit variability. Furthermore, blinded 
variability studies for both Doppler and M-mode measurements were conducted to 
ensure the results were reproducible and that meaningful comparisons could be 
drawn. The results are presented fully in chapter 3 and compare very favourably with 
any previously published data.
In Chapter 4 1 set out to non-invasively delineate the pathophysiology of 
fibrosis in hypertensive heart disease and to assess the clinical feasibility of using 
collagen markers in this setting. This is by far the largest study to date in this field. I 
enrolled a large cohort of well-characterised never treated hypertensives and used 
robust assays in standardised conditions. Measurement of PI CP, CITP and TIMP-1 
allowed firll assessment of the collagen equilibrium. My results demonstrate an 
increase in collagen synthesis, degradation and inhibition of degradation in untreated 
essential hypertension. Collagen synthesis and degradation appeared to be elevated 
throughout the cohort; however, TIMP-1 was only elevated amongst patients with
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established diastolic dysfunction. The remaining patients with normal diastolic filling 
had TIMP-1 levels comparable to normal subjects. Furthermore, there was no 
relationship between TIMP-1 and any index of systemic blood pressure or left 
ventricular mass. Therefore TIMP-1 levels are not elevated in hypertension per se but 
only in patients with diastolic dysfimction and fibrosis.
The other aim of this study was to assess the clinical utility of collagen 
markers as a non-invasive assessment of fibrosis. Diastolic dysfunction has been 
shown in animal and human models to be secondary to fibrosis and independent of 
myocyte hypertrophy. The presence of diastolic dysfunction was used as a surrogate 
for fibrosis in this study. Our results show TIMP-1 to be independent of blood 
pressure, to correlate with indices of diastolic filling and have a specificity and 
positive predictive value for diastolic dysfunction of over 95%. A measured TIMP- 
l>500rjg/l is an accurate and robust predictor of diastolic dysfunction and hence end- 
organ damage.
In summary, I have demonstrated using non-invasive markers of the collagen 
equilibrium that untreated essential hypertension is characterised by an increase in 
collagen synthesis, degradation and inhibition of degradation. The relative roles 
played by these processes in the resultant fibrosis cannot be determined by this study. 
Secondly, I demonstrated an association between biochemical markers of fibrosis and 
LV diastolic dysfunction in patients with untreated hypertension. In particular I 
identified TIMP-1 as a potential non-invasive marker of fibrosis. Further studies to 
investigate these markers as predictors of risk are needed and if positive will provide 
an important additional marker in the risk assessment of patients with hypertension.
In chapter 6, I enrolled a cohort of never treated patients with “white coat 
hypertension”. This was diagnosed on strict ambulatory blood pressure criteria. This
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was a particularly attractive cohort to study as the issue of interstitial changes in 
“white coat “ hypertension had never been addressed. Furthermore, by dividing our 
cohort into three groups according to 24hr blood pressure measurement we were able 
to assess at what blood pressure levels changes in the interstitium occur. The first 
notable finding was that TIMP-1 was normal throughout the cohort. This was 
consistent with our work in sustained hypertension, which shows TIMP-1 to be only 
elevated in the presence of diastolic dysfimction. Group 1 (mean daytime systolic 
BP>140mmHg) demonstrated an increment in collagen synthesis (PICP) and 
degradation (CITP). This group would contain patients with stage I hypertension 
however it is nonetheless notable that increased collagen synthesis and disruption to 
the equilibrium is occurring at the mild spectrum of disease. PI CP was normal in 
groups 2 and 3.
An additional finding of this study was that in groups 2 (mean daytime 
systolic BP 135-140mmHg) and group 3 (mean daytime systolic BP<135/85mmHg) 
there was a significant elevation in collagen degradation (CITP). Thus, even using 
the strictest definitions of normal ambulatory blood pressure (mean daytime systolic 
BP<135/85mmHg) there is evidence of disruption of the collagen equilibrium in 
patients with elevated ofiBce BP recordings.
Clearly, this study using non-invasive biochemical markers does not prove 
definitively that fibrosis is present in white coat hypertension. However, I have 
demonstrated a disruption of the collagen equilibrium with an increments in collagen 
degradation at all levels and an increment in collagen synthesis within group 1 of our 
cohort. These findings echo those demonstrated in sustained hypertension of which 
fibrosis is an accepted part. Therefore this allows us to hypothesise that changes in 
extracellular matrix leading to fibrosis occur in white coat hypertension.
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Therefore I have demonstrated disruption of the collagen equilibrium with 
increased collagen synthesis and degradation in patients with white coat hypertension. 
These changes occurred at blood pressure levels currently considered to fall within the 
normal range. These findings suggest that qualitative changes occur in the 
myocardium/vasculature in white coat hypertension at a very early stage. This has 
important implications in the ongoing debate regarding the clinical consequences of 
white coat hypertension, at what levels should hypertension be treated and also raises 
questions about what truly represents a normal ambulatory blood pressure in patients 
with elevated office readings.
Taking my results as a whole I have demonstrated that collagen markers are 
useful, robust non-invasive assessment of fibrosis. Within the context of hypertension 
we have demonstrated that TIMP-1 is a marker of fibrosis. We now have enough data 
to hypothesise about the temporal relationship and pathogenesis of fibrosis within 
hypertension. It appears that the first alteration to the collagen equilibrium is 
increment in degradation, presumably via up-regulation of MMPs, followed by 
increments in collagen synthesis. Inhibition of degradation, appears to play a central 
role only in more advanced stages, when fibrosis is present. These finding are 
consistent throughout the cohort of 150 never treated sustained hypertensives and 
“white coat” hypertensives.
Finally, in chapter 5 ,1 studied left ventricular hypertrophy occurring outwith 
the context of hypertension. Namely exercise induced left ventricular hypertrophy and 
in particular veteran athletes. The pathological significance and clinical consequences 
of exercise induced LVH is unclear and this is particularly relevant amongst veteran 
endurance athletes where studies have suggested incomplete regression of LVH on
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cessation of exercise. Using strict inclusion criteria I was able to enrol a population of 
veteran athletes with structural cardiac changes and without any co-morbidity. The 
aim of this study was to demonstrate, using biochemical markers, the presence of 
fibrosis in exercise induced LVH in a cohort of veteran athletes.
My results demonstrate that in elite veteran athletes there is biochemical 
evidence of disruption of the collagen equilibrium in comparison with a matched 
cohort of sedentary control subjects. Taking the cohort of athletes as a whole, there 
was a significant increase in collagen synthesis as assessed by an elevation in PICP, 
an increase in collagen degradation as assessed by an elevation in CITP and an 
increase in inhibition of degradation as assessed by an elevation in TIMP-1. Of more 
significance is the finding that athletes with echo evidence of exercise induced LVH 
(LVMI>130g/m^) had a further statistically significant elevation in TIMP-1. Indeed 
TIMP-1 was only elevated in athletes with LVH; the remaining athletes having TIMP- 
1 levels comparable to normal. Therefore, there only appears to be an elevated 
inhibition of degradation (TIMP-1) amongst athletes with LVH. This disruption of the 
collagen equilibrium amongst athletes with LVH, characterised by inhibition of 
collagen degradation, would favour the development of fibrosis. This contrasts with 
PICP and CITP, which were elevated throughout the cohort of athletes irrespective of 
the presence of LVH.
These findings suggest that increments in collagen synthesis and degradation 
occur at an early stage in the development of exercise induced cardiovascular 
adaptation. Whereas inhibition of collagen degradation occurs in more advanced 
stages of cardiovascular adaptation associated with established exercise induced 
hypertrophy.
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In conclusion, my results demonstrate that there is biochemical evidence of 
disruption of the collagen equilibrium favouring fibrosis in veteran athletes with 
LVH. This may suggest fibrosis occurs as part of the hypertrophic process of exercise 
induced LVH in veteran athletes and would provide a possible explanation for 
incomplete regression of LVH in this cohort.
Limitations
Many of the potential limitations of this study arise jfiom the use of non-invasive 
markers of fibrosis. A potential limitation relates to the reliability of the assay. 
However, as described in Chapter 3, the three assays used were robust and 
reproducible.
A firrther limitation arises from the fact that the assays are not specific to cardiac 
tissue or the vasculature. The three markers used, have been shown to be elevated in 
other conditions characterised by fibrosis, for example, hepatic cirrhosis. Therefore, 
every effort was made by a careful screening procedure to exclude subjects with 
conditions that may confound our results. I have listed the patients that were excluded 
prior to any analysis and were not recruited. This is a relatively small number as the 
General Practitioners referring the patients were given an exhaustive list of exclusion 
criteria which they kept to rigidly.
The collagen markers have been shown to have additional biological properties. I 
have listed some of the effects of TIMP-1 in the introduction. It must be accepted that 
some of these properties may have produced a confounding effect on my results. For 
example, TIMP-1 has haemopoetic-stimulating effects and therefore may have been
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stimulated by high intensity aerobic training and thus potentially influencing the 
results of the athletic cohort.
Finally, in the absence of cardiac biopsies the conclusions I have drawn have to be 
inferred from the non-invasive data available to me rather than presenting “gold 
standard” pathological evidence. However, the collagen markers used have been 
validated against cardiac biopsy findings and a biopsy study of this size would not 
have been feasible.
Further study is required to confirm and advance the findings of this study and to 
further delineate any potential clinical role for these collagen markers.
The study of a larger cohort of “ White coat” hypertensives would be appropriate 
allowing valid assessment of subgroups and allowing us to explore the continuous 
relationship between collagen metabolism and blood pressure.
A further study of a hypertensive cohort investigating vascular fibrosis rather than 
merely cardiac involvement and also investigating the effect, if any, of the common 
cardiovascular genetic polymorphisms on the collagen equilibrium would advance our 
knowledge and understanding fiorther.
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